

GenCore version 5.1.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 7, 2004, 21:46:38 ; Search time 6584 Seconds
(without alignments)
13039.491 Million cell updates/sec

Title: US-09-978-360A-32
Perfect score: 2356
Sequence: i atcttggcgccacagtgcg.....aaccaaaaaaaaaaaaaa 2356

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 32822875 seqs, 18219865908 residues

Total number of hits satisfying chosen parameters: 65645750

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST.*

1: gb_est1.*

2: gb_est2.*

3: gb_hic.*

4: gb_est3.*

5: gb_est4.*

6: gb_est5.*

7: gb_est6.*

8: gb_gss1.*

9: gb_gss2.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2354.4	99.9	2421	3	HSM805188
2	2311	98.1	2355	3	CR593496
3	1059	44.9	1059	9	AY417612
4	1012.4	43.0	1088	1	AL581422
5	1003.4	42.6	1160	5	EX340456
6	966	41.0	1046	5	EX342893
7	962	40.8	1142	1	AL563768
8	954.8	40.5	1042	5	BQ059008
9	946.8	40.2	1111	5	EX375981
10	904.8	38.4	1083	5	EX361590
11	890	37.8	981	5	EX342894
12	883.6	37.5	901	5	BQ059008
13	874.4	37.1	1100	4	BM920550
14	858	36.4	1039	5	EX334124
15	856.2	36.3	1039	1	AL530521
16	851.2	36.1	983	5	EX334447
17	848.2	36.0	1332	3	AK044088
18	848.2	36.0	3683	3	AK083295
19	848.2	36.0	3691	3	AK076419
20	847.2	36.0	1019	4	BM544329
21	846.6	35.9	1352	3	AK002416
22	844.4	35.8	933	5	EX370758
23	840.2	35.7	1141	4	BM806153
24	839.4	35.6	946	5	BU146835

```

25 837.2 35.5 1059 9 AY417614
26 837 35.5 913 5 BQ881855
27 835 35.4 845 5 BX364653
28 834.8 35.4 897 5 BU540823
29 825 35.0 885 5 BU542498
30 824.6 35.0 1087 5 EX402007
31 824.4 35.0 865 1 AL563662
32 815 34.6 985 5 BX354457
33 799.4 33.9 1067 4 BM922934
34 797.6 33.9 852 4 BM044182
35 793.8 33.7 980 1 AL559897
36 789.8 33.5 1028 5 EX402008
37 787.2 33.4 1036 4 BM561679
38 787 33.4 880 6 CA488482
39 786 33.4 935 5 BX334448
40 785 33.3 928 6 CA488412
41 780.2 33.1 816 4 BG680346
42 770.8 32.7 923 5 BX362069
43 765.8 32.5 873 4 BG681198
44 746.4 31.7 822 5 BX364654
45 745.6 31.6 868 4 BM048526

```

ALIGNMENTS

```

RESULT 1
HSM805188      2421 bp      mRNA      linear      HTC 03-AUG-2004
LOCUS          Homo sapiens mRNA; cDNA DKFZp762M0911 (from clone DKFZp762M0911).
DEFINITION     AL833889
ACCESSION      AL833889
VERSION        AL833889.1 GI:21739403
KEYWORDS       HTC.
SOURCE          Homo sapiens (human)
ORGANISM       Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 (bases 1 to 2421)
AUTHORS        Blum H., Bauersachs S., Mewes H.W., Weil B., Amid C., Osanger A.,
                Fobo G., Han M. and Wiemann S.
CONSTRM        The German cDNA Consortium
TITLE          Submitted (03-AUG-2004) MIPS, Ingolstaedter Landstr.1, D-85764
                Neuherberg, GERMANY
JOURNAL
COMMENT         Clone from S. Wiemann, Molecular Genome Analysis, German Cancer
                Research Center (DKFZ); Email s.wiemann@dkfz-heidelberg.de;
                sequenced by LMU (Ludwig Maximilians University, Munich/Germany)
                within the cDNA sequencing consortium of the German Genome Project.
                This clone (DKFZp762M0911) is available at the RZPD Deutsches
                Ressourcenzentrum fuer Genomforschung GmbH in Berlin, Germany.
                Please contact RZPD for ordering:
                http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp762M0911
                Further information about the clone and the sequencing project is
                available at http://mips.gsf.de/projects/cdna/.
FEATURES
Location/Qualifiers
1..2421
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="RZPD:DKFZp762M0911"
/db_xref="taxon:9606"
/clone="DKFZp762M0911"
/tissue_type="melanoma (MeWo cell line)"
/clone_lib="762 (synonym: hmel2). Vector pSport1; host
DH10B; sites NotI + SalI"
/dev_stage="adult"
/notes="hypotheical protein"
1..2421
/gene="DKFZp762M0911"
105..1163
/gene="DKFZp762M0911"
/codon_start=1
/product="hypotheical protein"
/protein_id="CAD38745.1"

```



```
1081 QY TACCCCTGTAAACAGCTAATAGTTTGGAAAGCGGCACAGCTTGACCTTGAAGCAGCCCTG 1140
1125 Db TACCCCTGTAAACAGCTAATAGTTTGGAAAGCGGCACAGCTTGACCTTGAAGCAGCCCTG 1184
1141 QY CCCCCTTTTTCAGGATTTTATCTCGAGGCTTTTGGAGGAGCAGTGGTGGGGGTAGCTGT 1200
1185 Db CCCCCTTTTTCAGGATTTTATCTCGAGGCTTTTGGAGGAGCAGTGGTGGGGGTAGCTGT 1244
1201 QY CACCTCCAGGTATGATTTGAGGGAGGAATTTGGGTAGAAACTTCCAGACCCATGCCCTCCAA 1260
1245 Db CACCTCCAGGTATGATTTGAGGGAGGAATTTGGGTAGAAACTTCCAGACCCATGCCCTCCAA 1304
1261 QY TGGCAGGATGCTGCTTTTCCACCTCAGAGGGGACCTGTCCATGTGCGCCTCATCAGA 1320
1305 Db TGGCAGGATGCTGCTTTTCCACCTCAGAGGGGACCTGTCCATGTGCGCCTCATCAGA 1364
1321 QY GCCTCACCTGGAGGATGCGGTGGCGTCTCTCCAGGAGCCAGATCAGTGGAGGTG 1380
1365 Db GCCTCACCTGGAGGATGCGGTGGCGTCTCTCCAGGAGCCAGATCAGTGGAGGTG 1424
1381 QY ACTGAAATGCCCTCATCACTTAAGCAACAAAGCCAGTGATCAGAGCTTCTTGTTCCTG 1440
1425 Db ACTGAAATGCCCTCATCACTTAAGCAACAAAGCCAGTGATCAGAGCTTCTTGTTCCTG 1484
1441 QY TGTCTTCTGTTTTTCTGTTGATCGTTGCTTGTGCTGTGACCTTGGTGGAGGACTCAGAG 1500
1485 Db TGTCTTCTGTTTTTCTGTTGATCGTTGCTTGTGCTGTGACCTTGGTGGAGGACTCAGAG 1544
1501 QY GGGAGGAAAGGCTGGGCCCCGAGTACAAACGATGCTTGGGTGCTGCTCCGAGAGACT 1560
1545 Db GGGAGGAAAGGCTGGGCCCCGAGTACAAACGATGCTTGGGTGCTGCTCCGAGAGACT 1604
1561 QY CTCGCGCAGCTTCTTCTTTTCTCTCATGCGCCCGGGAACAGTCTTCTTCAAGTGT 1620
1605 Db CTCGCGCAGCTTCTTCTTTTCTCTCATGCGCCCGGGAACAGTCTTCTTCAAGTGT 1664
1621 QY CAGCTGGGAGGCTCACTTGTGTTCTTCTTCCCTCAGCTGCTTGGCTTCTTAAAGGCTG 1680
1665 Db CAGCTGGGAGGCTCACTTGTGTTCTTCTTCCCTCAGCTGCTTGGCTTCTTAAAGGCTG 1724
1681 QY CAGTGTGTGTAGAGGACAAAGAAAGTGAAGTCAGCACATCCGCTTCTGCCAGATGGT 1740
1725 Db CAGTGTGTGTAGAGGACAAAGAAAGTGAAGTCAGCACATCCGCTTCTGCCAGATGGT 1784
1741 QY CGGGGCCCCGGGCAACAGATGAAGAGATCATGTGAAGGCGAGTGGTGCAGCAGGCC 1800
1785 Db CGGGGCCCCGGGCAACAGATGAAGAGATCATGTGAAGGCGAGTGGTGCAGCAGGCC 1844
1801 QY TCCTGGTTTCGCCACTGGCCCTGATTTGAATCTGCTGACCTTGGGAGAGCTCGGGGTGGT 1860
1845 Db TCCTGGTTTCGCCACTGGCCCTGATTTGAATCTGCTGACCTTGGGAGAGCTCGGGGTGGT 1904
1861 QY CCCTGGTTTTCCCTCTCGAGAAATGAGCGCAGAGGCTCGCCTCTTGAAGGACGCGAGTG 1920
1905 Db CCCTGGTTTTCCCTCTCGAGAAATGAGCGCAGAGGCTCGCCTCTTGAAGGACGCGAGTG 1964
1921 QY TGGATGCCACTGGCCTAGTGTCTGGCTTCACAGCTTCTTGAAGGCTGTCAAGGAA 1980
1965 Db TGGATGCCACTGGCCTAGTGTCTGGCTTCACAGCTTCTTGAAGGCTGTCAAGGAA 2024
1981 QY AAGCAGCGGCTGGCACCTCAGCATATGCCCTCTTGGGGCTCCCTCATCCAGCCGCTCG 2040
2025 Db AAGCAGCGGCTGGCACCTCAGCATATGCCCTCTTGGGGCTCCCTCATCCAGCCGCTCG 2084
2041 QY CAGCTTTGACATCTTGTGTGTAATCATGTGCTTCTTCTTGTGTATCCCTCCAGTAT 2100
2085 Db CAGCTTTGACATCTTGTGTGTAATCATGTGCTTCTTCTTGTGTATCCCTCCAGTAT 2144
2101 QY ACCATTGCCCTCACCTGCCCTTGGTACGCTTTTGTAGTCAAGACAGATGGGCTGTT 2160
2145 Db ACCATTGCCCTCACCTGCCCTTGGTACGCTTTTGTAGTCAAGACAGATGGGCTGTT 2204
2161 QY TCCCCCACTCTGAGTGTGGAGGTACATACACAGCTCTTTTTTTTATTGCGCTTTTCT 2220
2205 Db TCCCCCACTCTGAGTGTGGAGGTACATACACAGCTCTTTTTTTTATTGCGCTTTTCT 2264
2221 QY GCCTCTGAATGTTCATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 2280
2265 Db GCCTCTGAATGTTCATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 2324
2281 QY GCGGACACTAGTATGATGACAGTGTCCAGTGT 2311
2325 Db GCGGACACTAGTATGATGACAGTGTCCAGTGT 2355

RESULT 3
AY417612 1059 bp DNA linear GSS 12-DEC-2003
LOCUS Homo sapiens HCM6282 gene, VIRTUAL TRANSCRIPT, partial sequence,
DEFINITION genomic survey sequence.
ACCESSION AY417612
VERSION AY417612.1 GI:39773572
KEYWORDS GSS.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1059)
AUTHORS Clark,A.G., Glanowski,S., Nielson,R., Thomas,P., Kejariwal,A.,
Todd,M.A., Tanenbaum,D.M., Civello,D.R., Lu,F., Murphy,B.,
Ferriera,S., Wang,G., Zheng,X.H., White,T.J., Sninsky,J.J.,
Adams,M.D. and Cargill,M.
TITLE Inferring nonneutral evolution from human-chimp-mouse orthologous
gene trios
JOURNAL Science 302 (5652), 1960-1963 (2003)
PUBMED 14671302
REFERENCE 2 (bases 1 to 1059)
AUTHORS Clark,A.G., Glanowski,S., Nielson,R., Thomas,P., Kejariwal,A.,
Todd,M.A., Tanenbaum,D.M., Civello,D.R., Lu,F., Murphy,B.,
Ferriera,S., Wang,G., Zheng,X.H., White,T.J., Sninsky,J.J.,
Adams,M.D. and Cargill,M.
TITLE Direct Submission
JOURNAL Submitted (16-NOV-2003) Celera Genomics, 45 West Gude Drive,
Rockville, MD 20850, USA
COMMENT This sequence was made by sequencing genomic exons and ordering
them based on alignment.
FEATURES
source 1..1059
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
<1..>1059
/locus_tag="HCM6282"
gene
ORIGIN
Query Match 44.9%; Score 1059; DB 9; Length 1059;
Best Local Similarity 100.0%; Pred. No. 4.3e-269;
Matches 1059; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 42 ATGAGAGCGAGGCGCGCTCGCTGTCAGTTCATCTCTCCAGTTCATCTCTCGGCGCACCACCTCTGTG 101
Db 1 ATGAGAGCGAGGCGCGCTCGCTGTCAGTTCATCTCTCTCGGCGCACCACCTCTGTG 60
Qy 102 GTCAACCGCCCGCTGTACTCCGTGTACCGGCGAAGGCCCGGGTCTCCCAAGAGCTCAAG 161
Db 61 GTCAACCGCCCGCTGTACTCCGTGTACCGGCGAAGGCCCGGGTCTCCCAAGAGCTCAAG 120
Qy 162 GGAGCTAAAAAGTTCATTTGGGTGAAGATTAAAGAGTATCTTTCAGAGCTCCAGGA 221
Db 121 GGAGCTAAAAAGTTCATTTGGGTGAAGATTAAAGAGTATCTTTCAGAGCTCCAGGA 180
Qy 222 AAATGCGTGCCTTATGCTGTTATAGAAGGAGCTGTGGGCTGTGTTAAAGAAACGCTTAAC 281
Db 181 AAATGCGTGCCTTATGCTGTTATAGAAGGAGCTGTGGGCTGTGTTAAAGAAACGCTTAAC 240
Qy 282 AGCAGTTTGTGGAAAACCTGCAAGGGGGTAATTTCAGCGGCTGACACCTTCAGGAGCACAG 341
```

```
Db 241 AGCCAGTTTGTGAAACTGCAAGGGGTAAATTCAGCGCTGACATTCAGAGACAG 300
Qy 342 ATGGTGTGAATCGAACACCCACCTTTTGAATGATGCTCAAGATCATTCAGAGG 401
Db 301 ATGGTGTGAATCGAACACCCACCTTTTGAATGATGCTCAAGATCATTCAGAGG 360
Qy 402 ACCAACACAGTGCCTTTTCACTGTGTGCCCCAGGAGTGGGTGATGCTGTGCGA 461
Db 361 ACCAACACAGTGCCTTTTCACTGTGTGCCCCAGGAGTGGGTGATGCTGTGCGA 420
Qy 462 GTGCTGAAGCCCTTGAGTCACTGATGCTGTGGTCTAGAGACTGTGATGAGAAGTTCCAC 521
Db 421 GTGCTGAAGCCCTTGAGTCACTGATGCTGTGGTCTAGAGACTGTGATGAGAAGTTCCAC 480
Qy 522 CCCTCGATTCAGTCTTACCCATGTCATCGGCCATCATCAGCGGTGAGCGGCCCAA 581
Db 481 CCCTCGATTCAGTCTTACCCATGTCATCGGCCATCATCAGCGGTGAGCGGCCCAA 540
Qy 582 GGCATCCAGACACGAGGAGATGCTGAAGGTGGGGCCACCTCACAGGGGTGGCGAA 641
Db 541 GGCATCCAGACACGAGGAGATGCTGAAGGTGGGGCCACCTCACAGGGGTGGCGAA 600
Qy 642 GTGGTCTGGACAACTCTGTCGCTGTCAGCGGCCCAACAAAGCATGCGACTAT 701
Db 601 GTGGTCTGGACAACTCTGTCGCTGTCAGCGGCCCAACAAAGCATGCGACTAT 660
Qy 702 CTAAGCAGCAGGACTTCGACAGCTGCTGACAGGCGAGGATGAGCTCAGGCTCTGG 761
Db 661 CTAAGCAGCAGGACTTCGACAGCTGCTGACAGGCGAGGATGAGCTCAGGCTCTGG 720
Qy 762 AAGTGTCTGGGCTGGTCTTGGCTTGGCCATGTCACATGTCACACCTCTCTTCATCTCCGG 821
Db 721 AAGTGTCTGGGCTGGTCTTGGCTTGGCCATGTCACATGTCACACCTCTCTTCATCTCCGG 780
Qy 822 AAGCAGTATCTGACGCGCAGGAGCGCTGCGCTCAAGCAGATGACGAGGAGTTCAG 881
Db 781 AAGCAGTATCTGACGCGCAGGAGCGCTGCGCTCAAGCAGATGACGAGGAGTTCAG 840
Qy 882 GAGCATGAGGCCACCTGTCAGCGCAGCAGCAAGCTGAGGACAGGAGTCTGAAGAGC 941
Db 841 GAGCATGAGGCCACCTGTCAGCGCAGCAGCAAGCTGAGGACAGGAGTCTGAAGAGC 900
Qy 942 GCCTGTGATGTGCTGAGCAGCTTCAAGTCTGCTGCTTTCTGAGTGTGGGACAGTT 1001
Db 901 GCCTGTGATGTGCTGAGCAGCTTCAAGTCTGCTGCTTTCTGAGTGTGGGACAGTT 960
Qy 1002 TGTTCCTGACCGAGTGTACCGCGCTTGGCAGAGCCCAAGAGTGCCTATCTGCAGA 1061
Db 961 TGTTCCTGACCGAGTGTACCGCGCTTGGCAGAGCCCAAGAGTGCCTATCTGCAGA 1020
Qy 1062 CAGGGGATCAGCGGGTGTATACCCCTGTACACAGCTAA 1100
Db 1021 CAGGGGATCAGCGGGTGTATACCCCTGTACACAGCTAA 1059
```

RESULT 4

```
AL581422/c
LOCUS AL581422 Homo sapiens B CELLS (RAMOS CELL LINE) Homo sapiens cDNA
DEFINITION clone CS0DG003YC07 3-PRIME, mRNA sequence.
ACCESSION AL581422
VERSION AL581422.3 GI:46259998
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 1088)
AUTHORS Li, W.B., Gruber, C., Jessee, J., and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished (2001)
COMMENT On Feb 16, 2001 this sequence version replaced gi:31319662.
```

Contact: Genoscope

Genoscope - Centre National de Sequencage

BP 191 91006 EVRY cedex - France

Email: segref@genoscope.cns.fr, Web : www.genoscope.cns.fr
1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoRV sites of the pCMVSPORT 6 vector. Library was not normalized. Library was constructed by Life Technologies, a division of Invitrogen.

This sequence belongs to sequence cluster 670.r

For more information about this cluster, see

<http://www.genoscope.cns.fr/cdna?sa=CS0DG003AB04NFP1&c=670.r>.

FEATURES

source

1..1088

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="CS0DG003YC07"

/tissue_type="B CELLS (RAMOS CELL LINE)"

/cell_line="RAMOS CELL LINE"

/clone_lib="Homo sapiens B CELLS (RAMOS CELL LINE)"

/note="Vector: pCMVSPORT 6; 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoRV sites of the pCMVSPORT 6 vector. Library was not normalized."

ORIGIN

```
Query Match 43.0%; Score 1012.4; DB 1; Length 1088;
Best Local Similarity 93.9%; Pred. No. le-256;
Matches 1024; Conservative 42; Mismatches 21; Indels 3; Gaps 2;

Qy 1237 AACTCTCAGACCCATGCTTCAATGCGAGGATGCTGCTTCCACCTGAGGGGACC 1296
Db 1088 AAATTTCCMAAMCCYTCYCMATKSGAGATBT--CYTTCCMCYTGAGGGGCC 1031
Qy 1297 CTGTCATGTGCGAGCTCATCAGAGCCTCACCTGGGAGGATGCGTGCGTCTCTCCC 1356
Db 1030 YTKYCHWTGTSCACCTTCATCAGAGCCTCACCTGGGAGGATGCGTGCGTCTCTCTCC 971
Qy 1357 AGGAGCCAGATCAGTGGAGTGTGACTGAAATGCTCATCATTTAAGCACCACCAAGCCAG 1416
Db 970 AGGAGCCAGATCAGTGGAGTGTGACTGAAATGCTCATCATTTAAGCACCACCAAGCCAG 911
Qy 1417 TGATCAGAGCTCTTCTGCTCTGCTGCTTCTGTTTTTTCTGFGAATGCTGCTGCT 1476
Db 910 TGATCAGAGCTCTTCTGCTCTGCTGCTTCTGTTTTTTCTGFGAATGCTGCTGCT 851
Qy 1477 GTGGACTTGTGGAGGCTCAGAGGGAGGAGGAGCTGGGCCCCGAGTACACGAGTGC 1536
Db 850 GTGGACTTGTGGAGGCTCAGAGGGAGGAGGAGCTGGGCCCCGAGTACACGAGTGC 791
Qy 1537 TTGGGTGCTGCTCCGAAGAGACTCTGCCGAGCTTTTCTTCTTCTCTCATGCCCCGG 1596
Db 790 TTGGGTGCTGCTCCGAAGAGACTCTGCCGAGCTTTTCTTCTTCTCTCATGCCCCGG 731
Qy 1597 GAAACAGCTTTCTTTCAGATTGTGAGCTGGGAGGTCAACTGTGTCTCTTCTCCCTC 1656
Db 730 GAAACAGCTTTCTTTCAGATTGTGAGCTGGGAGGTCAACTGTGTGTCTTCTCTCCCTC 671
Qy 1657 ACCTGCTGCTCTTCAACGCTGCACTGTGTGTAGAGGACAAAGAAAGTGAAGTCAG 1716
Db 670 ACCTGCTGCTCTTCAACGCTGCACTGTGTGTGTAGAGGACAAAGAAAGTGAAGTCAG 611
Qy 1717 CACATCCGCTTCTGCCAGATGCTGGGGCCCCGGGCAACAGATTGAAGAGAGATCATGT 1776
Db 610 CACATCCGCTTCTGCCAGATGCTGGGGCCCCGGGCAACAGATTGAAGAGAGATCATGT 551
Qy 1777 GAAGGCGAGTTGGTCAGGACGCTCTCTGTTTTCGCCCATCGCCCTGATTTGAATCTCTG 1836
Db 550 GAAGGCGAGTTGGTCAGGACGCTCTCTGTTTTCGCCCATCGCCCTGATTTGAATCTCTG 491
Qy 1837 CCATTTGGGAGAGCTCGGGGTGCTCCCTGTTTTCCTCTCTGGAGATGAGCGCGAGAG 1896
```


Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 1142)
Li, W.B., Gruber, C., Jesse, J. and Polayes, D.
Full-length cDNA libraries and normalization
Unpublished (2001)
On Feb 15, 2001 this sequence version replaced gi:31287753.

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen. This sequence belongs to sequence cluster
670.r
For more information about this cluster, see
http://www.genoscope.cns.fr/cdna?s=CS0DD007AD08NP1&c=670.r.

FEATURES
source

Location/Qualifiers
1..1142
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DD007YG15"
/tissue="NEUROBLASTOMA COT 50-NORMALIZED"
/clone_lib="Homo sapiens NEUROBLASTOMA COT 50-NORMALIZED"
/notes="1st strand cDNA was primed with a NotI-oligo(dT)
primer. Five prime end enriched, double-strand cDNA was
digested with Not I and EcoR V sites of the Not I and EcoR V
sites of the pCMVSPORT 6 vector. Library was normalized."

ORIGIN

Query Match 40.8%; Score 962; DB 1; Length 1142;
Best Local Similarity 89.8%; Pred. No. 2.3e-243;
Matches 1025; Conservative 40; Mismatches 72; Indels 5; Gaps 4;

QY 1184 GTGGTGGGGTACGTGTCACCTCAGTATGATTGAGGAGGATTTGGGTAGAACTCTC 1243
DB 1137 GCGGGTAKGGGGKGTCTTTCCGCCCAATTTTATKARGCGGAGAAWTTGGGAAATAAT 1078
QY 1244 CAGACCATCGCTCCCAATGCGAGATGCTGCTTCCACCTGAGAGGACCTGTCCA 1303
DB 1077 TCAAACCATCTCCCAATGCGAGAGCTK--CTTTTCCACTTARRGGAACTKGCCT 1020
QY 1304 TGTGACGCTCATCAGAGCCTCACCTGGAGGATGCGTGGGCTCTCTCCAGGAGCC 1363
DB 1019 TG--GGARCTCTWTAAACCTTAACCTGGGAGGA-XSCGTGKGTCTCTCTCCAGGAGCC 962
QY 1364 AGATCAGTGGAGTGACCTGAAATGCTCATCATCTTAACCAACCAAGCGATGATCAG 1423
DB 961 AGATCAGTGGAGTATTAATGCAATGCTTAAAC--TAAGACCAAGCGAGTGTCTCG 903
QY 1424 CAGCTCTCTGCTGCTGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1483
DB 902 CAGCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 843
QY 1484 TGTGAGGAGTCTCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1543
DB 842 TGTGAGGAGTCTCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 783
QY 1544 CTGCTCTCAGAGGAGTCTGCGGAGCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1603
DB 782 CTGCTCTCAGAGGAGTCTGCGGAGCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 723
QY 1604 TCTTCTCTCAGAAATGTCAGGCTGGGAGGAGTCACTTGTGCTCTCTCTCTCTCTCTCTCTCT 1663
DB 722 TCTTCTCTCAGAAATGTCAGGCTGGGAGGAGTCACTTGTGCTCTCTCTCTCTCTCTCTCTCT 663
QY 1664 TGCCTCTCTCAGGCTGAGAGT 1723
DB 662 TGCCTCTCTCAGGCTGAGAGT 603


```
QY 541 CCGATGTCATCGGCCCACTACATCAGCGGTGAGCGGCCCAAGGCATCCCAAGAGACCGAGG 600
Db |||
QY 617 CCGATGTCATCGGCCCACTACATCAGCGGTGAGCGGCCCAAGGCATCCCAAGAGACCGAGG 676
Db |||
QY 601 AGATGCTGAAGGTGGGGGCCACCTCACA -GGGTTTGGGAACTGCTCTGGACAAACAAC 659
Db |||
QY 677 AGATGCTGAAGGTGGGGGCCACCTCACAAGGGGTTGGGAACTGCTCTGGACAAACAAC 736
Db |||
QY 660 TCTGTCGGCTCGAGCGGCCCAACCAAGGCATGACGACTATCTAAGCAGCAGGACTTC 719
Db |||
QY 737 TCTGTCGGCTCGAGCGGCCCAACCAAGGCATGACGACTATCTAAGCAGCAGGACTTC 796
Db |||
QY 720 GACAGCTCTGTCAGAGGAGGAGTCCAGGCTCAGGCTCTGGAAGCTGCTGGCGCTGGTT 779
Db |||
QY 797 GACAGCTCTGTCAGAGGAGGAGTCCAGGCTCAGGCTCTGGAAGCTGCTGGCGCTGGTT 856
Db |||
QY 780 TTTGGCTTTGCCACATGTCGCCACCTCTTCTTCAATCTCCGGAAGCAGTATCTGCAGCGG 839
Db |||
QY 857 TTTGGCTTTGCCACATGTCGCCACCTCTTCTTCAATCTCCGGAAGCAGTATCTGCAGCGG 916
Db |||
QY 840 CAGGAGCGCTCGGCTCAGGAGGAGTCCAGGCTCAGGCTCAGGCTCAGGCTCAGGCTCAGG 899
Db |||
QY 917 CAGGAGCGCTCGGCTCAGGAGGAGTCCAGGCTCAGGCTCAGGCTCAGGCTCAGGCTCAGG 975
Db |||
QY 900 CTGAGCGGAGCAAGGCTCAGGAGGAGTCCAGGCTCAGGCTCAGGCTCAGGCTCAGGCTCAGG 959
Db |||
QY 976 CTGAGCGGAGCAAGGCTCAGGAGGAGTCCAGGCTCAGGCTCAGGCTCAGGCTCAGGCTCAGG 1035
Db |||
QY 960 AGC 962
Db |||
QY 1036 AGC 1038
Db |||

RESULT 11
BX342894
LOCUS
DEFINITION
BX342894 Homo sapiens B CELLS (RAMOS CELL LINE) EST 07-APR-2004
Homo sapiens cDNA clone CS0DL007YCL16 5-PRIME, mRNA sequence.
ACCESSION
BX342894
VERSION
BX342894.2 GI:46275083
KEYWORDS
EST.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 981)
Li, W.-B., Gruber, C., Jessee, J. and Polayes, D.
Full-length cDNA libraries and normalization
Unpublished (2001)
On May 2, 2003 this sequence version replaced gi:30340129.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: segre@genoscope.cns.fr, Web : www.genoscope.cns.fr
1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen. This sequence belongs to sequence cluster
670.r
For more information about this cluster, see
http://www.genoscope.cns.fr/cdna?s=CS0DL007BB08QPl&c=670.r.
Location/Qualifiers
1..981
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DL007YCL16"
/cell_type="B CELLS (RAMOS CELL LINE) COT 25-NORMALIZED"
/clone_lib="Homo sapiens B CELLS (RAMOS CELL LINE) COT
25-NORMALIZED"
/note="1st strand cDNA was primed with a NotI-oligo(dT)
```

FEATURES

Source

primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."

ORIGIN

```
Query Match 37.8%; Score 890; DB 5; Length 981;
Best Local Similarity 99.6%; Pred. No. 2.8e-224;
Matches 923; Conservative 0; Mismatches 1; Indels 3; Gaps 3;
QY 1 ATCTTTGGCGCCACAGTCGGGCCACCGGGGCTCGCCCGCTCATGGAGAGCGAGGGCGGC 60
Db |||
QY 57 ATCTTTGGCGCCACAGTCGGGCCACCGGGGCTCGCCCGCTCATGGAGAGCGAGGGCGGC 116
Db |||
QY 61 CTTGGCTGTGCGAGTTTCCTCTCTGGGCAACCACTCTGTGTGTCACCGCGGCTCTACT 120
Db |||
QY 117 CTTGGCTGTGCGAGTTTCCTCTCTGGGCAACCACTCTGTGTGTCACCGCGGCTCTACT 176
Db |||
QY 121 CCGTGTACCGGAGAGGCGCGGGTCTCCCAAGAGCTCAAGGAGCTAAAAGTTCAAT 180
Db |||
QY 177 CCGTGTACCGGAGAGGCGCGGGTCTCCCAAGAGCTCAAGGAGCTAAAAGTTCAAT 236
Db |||
QY 181 TGGGTGAAGATTTAAAGAGTATTTCTTTAGAAAGCTCCAGGAAAATCGCTTATGCTG 240
Db |||
QY 237 TGGGTGAAGATTTAAAGAGTATTTCTTTAGAAAGCTCCAGGAAAATCGCTTATGCTG 296
Db |||
QY 241 TTATAGAGGAGCTGTGCGGTCTGTTAAAGAAACGCTTAAACAGCCAGTTTGGGAAAAT 300
Db |||
QY 297 TTATAGAGGAGCTGTGCGGTCTGTTAAAGAAACGCTTAAACAGCCAGTTTGGGAAAAT 356
Db |||
QY 301 GCAAGGGGTAATTCAGGCGCTGACACTTCAGGAGCAAGATGTTGTAATCGAATCGAACCA 360
Db |||
QY 357 GCAAGGGGTAATTCAGGCGCTGACACTTCAGGAGCAAGATGTTGTAATCGAATCGAACCA 416
Db |||
QY 361 CCCACCTTTGGAATGATTTGCTCAAGAGTCAATTCATCAGAGGACCAACACAGTGCCTTTC 420
Db |||
QY 417 CCCACCTTTGGAATGATTTGCTCAAGAGTCAATTCATCAGAGGACCAACACAGTGCCTTTC 476
Db |||
QY 421 ACTGTGTCGCCCAAGAGATGCGGTGATGTTGGTGTGTCAGTGTGAAGCCCTTGGACT 480
Db |||
QY 477 ACTGTGTCGCCCAAGAGATGCGGTGATGTTGGTGTGTCAGTGTGAAGCCCTTGGACT 536
Db |||
QY 481 CAGTGTGTCGGTCTAGAGACTGTGATGAGAAAGTTCCACCCCTCGATTTCAGTCTCTTCA 540
Db |||
QY 537 CAGTGTGTCGGTCTAGAGACTGTGATGAGAAAGTTCCACCCCTCGATTTCAGTCTCTTCA 596
Db |||
QY 541 CCGATGTCATCGGCCCACTACATCAGCGGTGAGCGGCCCAAGGCATCCCAAGAGACCGAGG 600
Db |||
QY 597 CCGATGTCATCGGCCCACTACATCAGCGGTGAGCGGCCCAAGGCATCCCAAGAGACCGAGG 656
Db |||
QY 601 AGATGCTGAAGGTGGGGGCCACCTCACAAGGGTGGGAACTGCTCTGGACAAACAAT 660
Db |||
QY 657 AGATGCTGAAGGTGGGGGCCACCTCACAAGGGTGGGAACTGCTCTGGACAAACAAT 716
Db |||
QY 661 CTGTCGGCTCGAGCGGCCCAACCAAGGCATGCTGCTCTATCTAAGCAGCAGGACTTCG 720
Db |||
QY 717 CTGTCGGCTCGAGCGGCCCAACCAAGGCATGCTGCTCTATCTAAGCAGCAGGACTTCG 776
Db |||
QY 721 ACAGCTCTGTCAGAGGAGGAGTCCAGGCTCAGGCTCTGGAAGGTGCTGGCGCTGGTT 780
Db |||
QY 777 ACAGCTCTGTCAGAGGAGGAGTCCAGGCTCAGGCTCTGGAAGGTGCTGGCGCTGGTT 836
Db |||
QY 781 TTGGCTTTGCCACATGTCGCCACCTCTTCTTCAATCTCCGGAAGCAGTATCTGCAG -CGG 839
Db |||
QY 837 TTGGCTTTG -CACATGTGCCACCTCTTCTTCAATCTCCGGAAGCAGTATCTGCAGCGG 895
Db |||
QY 840 CAGGAGCGCTCGGCTCAAGCAGATGAGGAGGTTCCAGGAGCATGAGGCCAGCTG 899
Db |||
QY 896 CAGGAGCGCTCGGCTCAAGCAGATGAGGAGGAGTT -CAGGAGCATGAGGCCAGCTG 954
Db |||
QY 900 CTGAGCGGAGCAAGGCTTGAGGACAGG 926
Db |||
QY 955 CTGAGCGGAGCAAGGCTTGAGGACAGG 981
Db |||
```

[illegible]

/clone_lib="NIH_MGC_122"
/note="Organ: pooled lung and spleen; Vector: pCMV-SPORT6;
Site_1: NotI; Site_2: EcoRV (destroyed); RNA source
anonymous pool of 24 week female lung, 16 week female
spleen, and 20-22 week male spleens. Library is oligo-dT
primed and directionally cloned (EcoRV site is destroyed
upon cloning). Average insert size 1.4 kb, insert size
range 1-3 kb. Library is normalized and enriched for
full-length clones and was constructed by C. Gruber
(Invitrogen). Research Genetics tracking code 026. Note:
this is a NIH_MGC Library."

ORIGIN

Query Match 37.1%; Score 874.4; DB 4; Length 1100;
Best Local Similarity 94.1%; Pred. No. 3.9e-220;
Matches 964; Conservative 0; Mismatches 51; Indels 9; Gaps 5;

QY 1 ATCTTTGGCGCCACAGTCGCGCCACCGGGGCTCGCCCGCTCATGAGAGCGGAGCGGCGG 60
DB ATCTTTGGCGCCACAGTCGCGCCACCGGGGCTCGCCCGCTCATGAGAGCGGAGCGGCGG 134
QY 61 CCTCGTGTGCAGTTTCCTCTCTGGGCACACCTCTGTGTGTCACCGCGGCCCTGTACT 120
DB CCTCGTGTGCAGTTTCCTCTCTGGGCACACCTCTGTGTGTCACCGCGGCCCTGTACT 194
QY 121 CGTGTACCGGCAGAGGCGCGGCTCTCCACAGAGCTCAAGGAGCTAAAGATTCATT 180
DB CGTGTACCGGCAGAGGCGCGGCTCTCCACAGAGCTCAAGGAGCTAAAGATTCATT 254
QY 181 TGGGTGAAGATTTAAAGATTTCTTTTTCAGAGCTCCAGGAAATCGTGCTTATGCTG 240
DB TGGGTGAAGATTTAAAGATTTCTTTTTCAGAGCTCCAGGAAATCGTGCTTATGCTG 314
QY 241 TTATAGAGAGAGCTGTGCGGTCTGTTTAAAGAAACGCTTAAAGCCAGTTTGTGAAACT 300
DB TTATAGAGAGAGCTGTGCGGTCTGTTTAAAGAAACGCTTAAAGCCAGTTTGTGAAACT 374
QY 301 GCAAGGGGTAAATTCAGCGGCTGACACTTCAGGAGCACAGATGTGTCGATTCGAACCA 360
DB GCAAGGGGTAAATTCAGCGGCTGACACTTCAGGAGCACAGATGTGTCGATTCGAACCA 434
QY 361 CCCACCTTTGGAATGATGCTCAAGATCATTCATCAGAGGACCAACACAGATGCCCTTTG 420
DB CCCACCTTTGGAATGATGCTCAAGATCATTCATCAGAGGACCAACACAGATGCCCTTTG 494
QY 421 ACTGTGTCCCAAGAGATGCGGTGGATGTGCTGTGAGTGTGTCGAGTGTGAAGCCCTGGAT 480
DB ACTGTGTCCCAAGAGATGCGGTGGATGTGCTGTGAGTGTGTCGAGTGTGAAGCCCTGGAT 554
QY 481 CAGTGGATCTGGTCTPAGAGACTGTGTATGAGAAGTTCACCCCTCGATTCAGTCCCTCA 540
DB CAGTGGATCTGGTCTPAGAGACTGTGTATGAGAAGTTCACCCCTCGATTCAGTCCCTCA 614
QY 541 CCGATGTCTACGCGCCACTACATCAGCGGTGAGCGGCCCAAGGCATCCAGAGACCGAGG 600
DB CCGATGTCTACGCGCCACTACATCAGCGGTGAGCGGCCCAAGGCATCCAGAGACCGAGG 674
QY 601 AGATGCTGAAGTGGGGGCACCTCACAAGGGTTGGGAACTGTGTCCTGGACAACT 660
DB AGATGCTGAAGTGGGGGCACCTCACAAGGGTTGGGAACTGTGTCCTGGACAACT 734
QY 661 CTGTCCGCTCGAGCGCCCAACAGGAGTGCAGTACTATCTAAGCAGCCAGGACTTCG 720
DB CTGTCCGCTCGAGCGCCCAACAGGAGTGCAGTACTATCTAAGCAGCCAGGACTTCG 794
QY 721 ACAGCTGTCTGAGAGCGGAGTTCAGCGGTTCAGGCTCTGGAAGTGTCTGGCGCTGTTT 780
DB ACAGCTGTCTGAGAGCGGAGTTCAGCGGTTCAGGCTCTGGAAGTGTCTGGCGCTGTTT 854
QY 781 TTGGCTTTGACATGTGCCACCTCTCTTCA-TTCTCCGGAAGCAGTATCTGACGGG 839
DB TTGGCTTTGACATGTGCCACCTCTCTTCA-TTCTCTCGGGAAGCAGTATCTGACGGG 914

QY 840 CAGGAGCGGCTG-CGCTCAAGCAGATGCAGG-AGGAGTTCAGGAGCATGAGGCCAGC 897
DB CAGGAGCGGCTGCGCGCTCAAGCAATGCGGAAGGAGTTCAGGAAGCATGAGGCCAC 974
QY 898 TGTGAGCGGAGCAGCAAGCC--TGAGGACAGGAGAGTCTGAAGAGCGCTGTGTAGTGTG 955
DB TGTGAGCGGAGCAGCAAGCCCTGAGAACAGAGGAAATTTGAAATAATGCTGTGTATGGG 1034
QY 956 TGTGAGCAGCTCAAGTCCT---CGTCTTTCTGAGTGTGGCAGCTTTGTTCCTGCA 1011
DB TGTGAGCAGCTTTAAGCCTGCGCGCTTTCTTGAAGTGGGGCGCTTTGTTCTCTCAC 1094
QY 1012 CCGA 1015
DB 1095 CCAA 1098

RESULT 14
BX334124 1039 bp mRNA linear EST 07-APR-2004
LOCUS BX334124
DEFINITION BX334124 Homo sapiens NEUROBLASTOMA COT 50-NORMALIZED Homo sapiens
cDNA clone CS0DD007YL23 5-PRIME, mRNA sequence.
ACCESSION BX334124
VERSION BX334124.2 GI:46266395
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 1039)
AUTHORS Li, W.B., Gruber, C., Jessee, J., and Pollay, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished (2001)
COMMENT On May 1, 2003 this sequence version replaced gi:30312282.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqrefgenoscope.cns.fr, Web : www.genoscope.cns.fr
1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen. This sequence belongs to sequence cluster
670.r

For more information about this cluster, see
http://www.genoscope.cns.fr/cdna?s=CS0DD007CF12QPl&c=670.r.
Location/Qualifiers
1. .1039
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DD007YL23"
/tissue type="NEUROBLASTOMA COT 50-NORMALIZED"
/clone_lib="Homo sapiens NEUROBLASTOMA COT 50-NORMALIZED"
/note="1st strand cDNA was primed with a NotI-oligo(dT)
primer. Five prime end enriched, double-strand cDNA was
digested with Not I and cloned into the Not I and EcoR V
sites of the pCMVSPORT 6 vector. Library was normalized."

FEATURES
source

ORIGIN

Query Match 36.4%; Score 858; DB 5; Length 1039;
Best Local Similarity 88.7%; Pred. No. 8.6e-216;
Matches 865; Conservative 75; Mismatches 32; Indels 3; Gaps 3;

QY 1 ATCTTTGGCGCCACAGTCGCGCCACCGGGGCTCGCCCGCTCATGAGAGCGGAGCGGCGG 60
DB AGCCGKGCGCCACAGKSGGCSACCGGGCKCGCCGCKCAKAGAGAGCGGAGGCGGC 126
QY 61 CTCTGCTGTGCAGTTCATCTCTCTGGGACACCTCTGTGTGTCTACCGCGCCCTGTACT 120
DB CCKCGKKGCCAGKGCACCGCGGGCACCCCKCKGGGCKACCGCGCCCTGGACT 186
QY 121 CGTGTACCGCAGAGAGGCCCGGGTCTCCCAAGAGCTCAAGGAGCTAAAAAGTTTATT 180

```
187 CCGTGTACCGCAGAGGCCCGGTCKCCACAGCKCAAGGCGCAARRAGTTCATT 246
181 TGGGTGAAGATTAAAGAGTATTTCTTTCAGAACTCCAGGAAAATCGTGCCTTATGCTG 240
247 KGGGKAAGAKKAAAGAGKATCTTTTCAAGCGCCAGGAAAAGKCGKCTGAKGCGG 306
241 TTATAGAGAGCTGTGCGGTCTGTTTAAAGAAACGCTTAACAGCCAGTTTGTGGAAACT 300
307 TGATAGAGGRCGGGTGCGNKKGTGAAGAAACGCTTAAACGCCAGTGTGTGGAAACK 366
301 GCAAGGGGTAAATTCAGCGGCTGACACTTCAGGAGCACAGATGGTGTGAATCGAACCA 360
367 GCAAGGGGKAAATTCAGCGGCTGACACTTCAGGAGCACAGAGKGGGTGAATCGAACCA 426
361 CCCACCTTTTGGAAATGATGCTTAAAGATCATTCATCAGAGGACAAACAGTGCCTTTG 420
427 CCCACCTTTTGGATGATGCTKCAAGAKATTCATCAGAGGACCAACACAGTGCCTTTG 486
421 ACCTGTGCCCCACAGAGGATGGCGTGTGATGCTGTGCGAGTGTGCGAGCTGCCTGACT 480
487 ACCTGTGCCCCACAGAGGATGGCGTGTGATGCTGTGCGAGTGTGCGAGCTGCCTGACT 546
481 CAGTGGATCTGGGTCTAGAGACTGTGTATGAGAAAGTTCCACCCCTCGATTTCCTTCA 540
547 CAGTGGATCTGGGTCTAGAGACTGTGTATGAGAAAGTTCCACCCCTCGATTTCCTTCA 606
541 CCGATGTCATCGGCCATACATCAGCGGTGAGCGGCCAAAGGATCCAAAGACCGAGG 600
607 CCGATGTCATCGGCCATACATCAGCGGTGAGC-GSCCAAAGGCATCCAAAGACCGAGG 665
601 AGATGCTGAAGTGGGGGCCACCCCTCACAGGGGTTGGCGAACTGGTCTGGACAACAACT 660
666 AGATGCTGAAGTGGGGGCCACCCCTCACAGGGGTTGGCGAACTGGTCTGGACAACAACT 725
661 CTGTCCGCTGACAGCGCCCAACAAAGGCATGAGTACTATCTAAGCAGCAGGACTTCG 720
726 CTGTCCGCTGACAGCYKTTTWWACAGGCATGAGTCTATCTAAGCAGCAGGACTTCG 785
721 ACAGCTGCTGACAGGAGGAGTGCAGCGTCAAGGCTGAGGAGTGTGCGCGCTGGTTT 780
786 ACAGCTGCTGACAGGAGGAGTGCAGCGTCAAGGCTGAGGAGTGTGCGCGCTGGTTT 845
781 TTGGCTTTGCCACATGTGCCACCTCTTCTTCACTTCCGGAAGCATCTCAG-CGG 839
846 TTGGCTTTGMAWGTGGCCACCCTCTTCTTCACTTCCGGAAGCATGTTCTGCMSCGG 905
840 CAGGAGCGCTGCGCCTCAAGCAGATGACAGGAGGTTCCAGGAGCATGAGGCCAGCTG 899
906 CAGGGGSCCTGSCCTTAAGCAGATGACAGGAGGTTCCAMGRGCATGAGGCCMM-CYG 964
900 CTGAGCGGACCAAGCTGAGGACAGGAGTCTGAAGAGCGCTGTGTAGTGTGCTG 959
965 CYGAGCCSAGCCAACTGAGRSRGRGAGTTTAAARAGCGCCCTTTTGTGTGTTT 1024
960 AGCAGCTTCAAGTCC 974
1025 AMMCCYTCAAATCC 1039
```

```
RESULT 15
AL530521
LOCUS
DEFINITION AL530521 Homo sapiens NEUROBLASTOMA COT 50-NORMALIZED Homo sapiens
cDNA clone CS0DD007YGI5 5-PRIME, mRNA sequence.
ACCESSION AL530521
VERSION AL530521.3 GI:45705485
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1039)
```

AUTHORS
TITLE
JOURNAL
COMMENT

Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
Full-length cDNA libraries and normalization
Unpublished (2001)
On Feb 13, 2001 this sequence version replaced gi:31068354.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime
end enriched, double-strand cDNA was digested with Not I and cloned
into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library
was normalized. Library was constructed by Life Technologies, a
division of Invitrogen. This sequence belongs to sequence cluster
670.r

For more information about this cluster, see
http://www.genoscope.cns.fr/cdha?S=CS0DD007AD080Plk=670.r.

FEATURES
source

Location/Qualifiers
1..1039
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DD007YGI5"
/tissue_type="NEUROBLASTOMA COT 50-NORMALIZED"
/clone_lib="Homo sapiens NEUROBLASTOMA COT 50-NORMALIZED"
/note="1st strand cDNA was primed with a NotI-oligo(dT)
primer. Five prime end enriched, double-strand cDNA was
digested with Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."

ORIGIN

Query Match 36.3%; Score 856.2; DB 1; Length 1039;
Best Local Similarity 92.9%; Pred. No. 2.6e-215;
Matches 891; Conservative 23; Mismatches 42; Indels 3; Gaps 2;
QY 1 ATCTTTGGGCCACAGTCGGCCACCGGGGCTCCGCCGCTCATGGAGAGCGAGGCGGC 60
Db 41 ATCTTTGGGCCACAGTCGGCCACCGGGGCTCCGCCGCTCATGGAGAGCGAGGCGGC 100
QY 61 CCTCGTGTGCCAGTTCATCTCTCTGGGACCACTCTGTGGTTCAGCGCGCTGTACT 120
Db 101 CCTCGTGTGCCAGTTCATCTCTCTGGGACCACTCTGTGGTTCAGCGCGCTGTACT 160
QY 121 CCGTGTACCGGAGAGGCGCGGCTCTCCCAAGAGCTCAAGGAGCTTAAAAAGTTCATT 180
Db 161 CCGTGTACCGGAGAGGCGCGGCTCTCCCAAGAGCTCAAGGAGCTTAAAAAGTTCATT 220
QY 181 TGGGTGAAGATTAAAGAGTATTTCTTCAAGAGCTCCAGGAAAATCGTGCCTTATGCTG 240
Db 221 TGGGTGAAGATTAAAGAGTATTTCTTCAAGAGCTCCAGGAAAATCGTGCCTTATGCTG 280
QY 241 TTATAGAGGAGCTGTGCGGTCTGTTTAAAGAAACGCTTAACAGCCAGTTTGTGGAAACT 300
Db 281 TTATAGAGGAGCTGTGCGGTCTGTTTAAAGAAACGCTTAAYAGCCAGTTTGTGGAAACT 340
QY 301 GCAAGGGGTAAATTCAGCGGCTGACACTTCAGGAGCACAGATGGTGTGAATCGAACCA 360
Db 341 GCAAGGGGTAAATTCAGCGGCTGACACTTCAGGAGCACAGATGGTGTGAATCGAACCA 400
QY 361 CCCACCTTTTGGAAATGATGCTTAAAGATCATTCATCAGAGGACCAACAGTGCCTTTG 420
Db 401 CCCACCTTTTGGAAATGATGCTTAAAGATCATTCATCAGAGGACCAACAGTGCCTTTG 460
QY 421 ACCTGTGCCCCACAGGATGGCGTGTGATGCTGTGCGAGTGTGCGAGCTGCCTGACT 480
Db 461 ACCTGTGCCCCACAGGATGGCGTGTGATGCTGTGCGAGTGTGCGAGCTGCCTGACT 520
QY 481 CAGTGGATCTGGGTCTAGAGACTGTGTATGAGAAAGTTCCACCCCTCGATTTCCTTCA 540
Db 521 CAGTGGATCTGGGTCTAGAGACTGTGTATGAGAAAGTTCCACCCCTCGATTTCCTTCA 580
QY 541 CCGATGTCATCGGCCATACATCAGCGGTGAGCGGCCAAAGGATCCAAAGACCGAGG 600
Db 581 CCGATGTCATCGGCCATACATCAGCGGTGAGCGGCCAAAGGATCCAAAGACCGAGG 640


```
QY 601 AGATGCTGAAGTGGGGCCACCCTCACAGGGGTTGGGGAAGTGTCTCTGGACAACT 660
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 641 AGATGCTGAAGTGGGGGCCACCCCTCACAGGGGTTGGGGAAGTGTCTCTGGACAACT 700
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 661 CTGTCCGCTGTGAGCGCGCCCAAAACAAGGCATGCAGTACTATCTAAGCAGCCAGGACTTCG 720
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 701 CTGTTTCGCTGTGAGCGCGCCCAAAACAAGGCATGCAGTACTATCTAAGCAGCCAGGACTTCG 760
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 721 ACAGCCTGTGTGAGAGGAGGAGTGCAGCGTCAGGCTCTGGAAAGTGTGGCGCTGGTTT 780
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 761 ACAGCCTGTGTGAGAGGAGGAGTGCAGCGTTCAGGCTCTGGAAAGTGTGGCGCTGGTTT 820
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 781 TTGGCTTTGCCACATGTGCCACCTCTTCTTCAATCTCCGGAAGCAGTATCTGAGCGGC 840
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 821 TTGGCTTTGCCACATGTGCCACCTCTTCTTCAATCTCCGGAAGCAGTATCTGAGCGGC 880
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 841 AGGAGCGCTGTGCGCTCAAGCAGATGCAGGAGGAGTTCAGGAGCATGAGGCCAGCTGC 900
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 881 AGGAGSCCTTCGCTTAAGCAGATGCAGAGGAG-TCCAVGAGCMTKAHGGCCACCCGY 939
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 901 TGAGCGGAGCCAGCCTGAGGACAGGAGAGTCTGAAGAGCGCCTGTGTAGTGTCTG 959
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
QY 940 --GACCCGACCAAGCYTGAGGMAAGAAATTTAARACGCTTTTGTGTTTTTRACCG 996
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
```

Search completed: November 8, 2004, 02:50:31
Job time : 6593 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 6, 2004, 17:38:28 ; Search time 142 Seconds
(without alignments)
875.602 Million cell updates/sec

Title: US-09-978-360A-437

Perfect score: 1831

Sequence: 1 MESGGPSLCQFILLGTTSV.....PKKPCICQAIRTVPLVNS 352

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1566620 seqs, 353225886 residues

Total number of hits satisfying chosen parameters: 1566620

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA:*

1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/2/pubpaa/US10D_PUBCOMB.pep.*
17: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep.*
18: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep.*
19: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep.*
20: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1831	100.0	352	11	US-09-978-360A-437
2	1831	100.0	352	14	US-10-024-298A-75
3	1831	100.0	352	14	US-10-042-211A-75
4	1831	100.0	352	14	US-10-315-664-105
5	1831	100.0	352	15	US-10-221-625-25
6	1831	100.0	352	15	US-10-169-395-92
7	1831	100.0	352	15	US-10-617-217A-75
8	1831	100.0	352	17	US-10-024-298A-75
9	1826	99.7	392	9	US-09-764-864-801
10	1824	99.6	352	14	US-10-024-298A-73
11	1824	99.6	352	14	US-10-042-211A-73
12	1824	99.6	352	15	US-10-617-217A-73
13	1824	99.6	352	17	US-10-024-298A-73

14	901	49.2	174	9	US-09-764-864-1262	Sequence 1262, Ap
15	854	46.6	165	15	US-10-264-237-2680	Sequence 2680, Ap
16	295	16.1	339	15	US-10-424-599-158556	Sequence 158556, Ap
17	288.5	15.8	343	17	US-10-425-115-364826	Sequence 364826, Ap
18	267.5	14.6	338	17	US-10-739-930-6185	Sequence 6185, Ap
19	262	14.3	350	17	US-10-425-115-364805	Sequence 364805, Ap
20	252.5	13.8	375	17	US-10-739-930-10614	Sequence 10614, A
21	231	12.6	332	15	US-10-425-114-47706	Sequence 47706, A
22	214	11.7	358	15	US-10-424-599-224671	Sequence 224671, A
23	213	11.6	310	16	US-10-437-963-111394	Sequence 111394, A
24	195.5	10.7	378	16	US-10-437-963-138606	Sequence 138606, A
25	188.5	10.3	332	14	US-10-195-144-83	Sequence 83, Appl
26	188.5	10.3	332	14	US-10-345-072-83	Sequence 83, Appl
27	184.5	10.1	163	15	US-10-425-114-65305	Sequence 65305, A
28	183	10.0	236	15	US-10-425-114-38446	Sequence 38446, A
29	183	10.0	236	17	US-10-425-115-253264	Sequence 253264, A
30	172	9.4	366	17	US-10-739-930-7102	Sequence 7102, Ap
31	163	8.9	257	9	US-09-949-842-14	Sequence 14, Appl
32	163	8.9	403	13	US-10-087-192-114	Sequence 114, Appl
33	155.5	8.5	303	14	US-10-094-749-2475	Sequence 2475, Ap
34	155.5	8.5	696	14	US-10-094-749-2425	Sequence 2425, Ap
35	155.5	8.5	723	14	US-10-104-047-2572	Sequence 2572, Ap
36	148.5	8.1	272	15	US-10-108-260A-4608	Sequence 4608, Ap
37	145.5	7.9	336	15	US-10-451-168-89	Sequence 89, Appl
38	144.5	7.9	169	17	US-10-425-115-364837	Sequence 364837, Ap
39	144.5	7.9	438	8	US-08-464-588-2	Sequence 2, Appl
40	144.5	7.9	438	14	US-10-323-643-2	Sequence 323, Appl
41	144.5	7.9	618	14	US-10-153-668-338	Sequence 338, Appl
42	144.5	7.9	618	14	US-10-207-655-200	Sequence 200, Appl
43	144.5	7.9	618	14	US-10-232-286-2	Sequence 2, Appl
44	144.5	7.9	618	14	US-10-366-307-4	Sequence 4, Appl
45	144.5	7.9	618	15	US-10-361-270-3	Sequence 3, Appl

ALIGNMENTS

RESULT 1

US-09-978-360A-437
; Sequence 437, Application US/09978360A
; Publication No. US20040110939A1
; GENERAL INFORMATION:
; APPLICANT: Edwards, Jean-Baptiste Dumas Milne
; APPLICANT: Duclert, Aymeric
; APPLICANT: Bougueleret, Lydie
; APPLICANT: Jobert, Severin
; APPLICANT: Clusel, Catherine
; TITLE OF INVENTION: Complementary DNA's Encoding Proteins with Signal Peptides
; FILE REFERENCE: 56.USA.CIP
; CURRENT APPLICATION NUMBER: US/09/978,360A
; CURRENT FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: US 60/066,677
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: US 60/069,957
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: US 60/074,121
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: US 60/081,563
; PRIOR FILING DATE: 1998-04-13
; PRIOR APPLICATION NUMBER: US 60/096,116
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: US 60/099,273
; PRIOR FILING DATE: -09-04
; PRIOR APPLICATION NUMBER: US 09/191,997
; PRIOR FILING DATE: 1998-11-13
; PRIOR APPLICATION NUMBER: US 09/215,435
; PRIOR FILING DATE: 1998-12-17
; PRIOR APPLICATION NUMBER: PCT/IB98/02122
; PRIOR FILING DATE: 1998-12-17
; PRIOR APPLICATION NUMBER: US 09/247,155
; PRIOR FILING DATE: 1999-02-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 810

```
; SOFTWARE: Patent.pm
; SEQ ID NO 437
; LENGTH: 352
; TYPE: PRT
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -23..-1
US-09-978-360A-437

Query Match      100.0%; Score 1831; DB 11; Length 352;
Best Local Similarity 100.0%; Pred. No. 1.6e-162;
Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MESGGPRLSCQFILLGTTTSVVTAAALYSVYRQKARVSQELKGAKKVLHGDLKSLSEAPG 60
Db      1 MESGGPRLSCQFILLGTTTSVVTAAALYSVYRQKARVSQELKGAKKVLHGDLKSLSEAPG 60
QY      61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKVMWNRTHLWDCSKIIHOR 120
Db      61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKVMWNRTHLWDCSKIIHOR 120
QY      121 TMTVPDLVPHEDGVAVRVLKPLDSVDLGLTVYVEKEFHPISQSFDTDVIGHYISGERPK 180
Db      121 TMTVPDLVPHEDGVAVRVLKPLDSVDLGLTVYVEKEFHPISQSFDTDVIGHYISGERPK 180
QY      181 GQOETEMLKVGATLTGVLGELVDNNSVRLQPPKQGMYYLSSQDFDLSLLQROESSVRLW 240
Db      181 GQOETEMLKVGATLTGVLGELVDNNSVRLQPPKQGMYYLSSQDFDLSLLQROESSVRLW 240
QY      241 KVALVFGATCATLFFILRKQYLOERLRLKQMOEFOEHEAQLLSRAKPEDRESLKS 300
Db      241 KVALVFGATCATLFFILRKQYLOERLRLKQMOEFOEHEAQLLSRAKPEDRESLKS 300
QY      301 ACVCLSSFKSCVFLGCHVCSCTCYRALPEPKKPCICRQAITRVIPLYS 352
Db      301 ACVCLSSFKSCVFLGCHVCSCTCYRALPEPKKPCICRQAITRVIPLYS 352

RESULT 3
US-10-042-211A-75
; Sequence 75, Application US/10042211A
; Publication No. US20030170719A1
; GENERAL INFORMATION:
; APPLICANT: MATSUDA, Akio et al.
; TITLE OF INVENTION: NFkB Activating Gene
; FILE REFERENCE: 1254-0192P
; CURRENT APPLICATION NUMBER: US/10/042,211A
; CURRENT FILING DATE: 2002-01-11
; PRIOR APPLICATION NUMBER: JP 2000-402288
; PRIOR FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: JP 2001-088912
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: JP 2001-254018
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: US 60/258,315
; PRIOR FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: US 60/278,640
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 60/314,385
; PRIOR FILING DATE: 2001-08-24
; NUMBER OF SEQ ID NOS: 182
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 75
; LENGTH: 352
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-042-211A-75

Query Match      100.0%; Score 1831; DB 14; Length 352;
Best Local Similarity 100.0%; Pred. No. 1.6e-162;
Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MESGGPRLSCQFILLGTTTSVVTAAALYSVYRQKARVSQELKGAKKVLHGDLKSLSEAPG 60
Db      1 MESGGPRLSCQFILLGTTTSVVTAAALYSVYRQKARVSQELKGAKKVLHGDLKSLSEAPG 60
QY      61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKVMWNRTHLWDCSKIIHOR 120
Db      61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKVMWNRTHLWDCSKIIHOR 120
QY      121 TMTVPDLVPHEDGVAVRVLKPLDSVDLGLTVYVEKEFHPISQSFDTDVIGHYISGERPK 180
Db      121 TMTVPDLVPHEDGVAVRVLKPLDSVDLGLTVYVEKEFHPISQSFDTDVIGHYISGERPK 180

; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 75
; LENGTH: 352
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-024-298A-75
; Sequence 75, Application US/10024298A
; Publication No. US20030143540A1
; GENERAL INFORMATION:
; APPLICANT: ASAH KASEI KABUSHIKI KAISHA
; APPLICANT: AKIO MATSUDA
; APPLICANT: GOICHI HONDA
; APPLICANT: SHUJI MURAMATSU
; APPLICANT: YUKIO NAGANO
; TITLE OF INVENTION: NF-K B Activating Gene
; FILE REFERENCE: 1254-0191P
; CURRENT APPLICATION NUMBER: US/10/024,298A
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 60/314,385
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: 60/278,641
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: 60/258,315
; PRIOR FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: JP254018/2001
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: JP0088912/2001
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: JP402288/2000
; PRIOR FILING DATE: 2000-12-28
; NUMBER OF SEQ ID NOS: 182
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 75
; LENGTH: 352
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-024-298A-75
```

Db 121 TTTVPFDLVPHEDGVDVAVRVLPKLDSDVLGLTVEYKFPSPISQSFDTDVIGHYISGERPK 180
Qy 181 GIQTEMLKVGATLTGVELVLDNNSVRLQPPKQGMYYLSSQDFDLSLQROESSVRLW 240
Db 181 GIQTEMLKVGATLTGVELVLDNNSVRLQPPKQGMYYLSSQDFDLSLQROESSVRLW 240
Qy 241 KVLALVGFATCATLFFILRKQYLRQERLRLKQMEEFQHEAQLLSRAKPEDRESLKS 300
Db 241 KVLALVGFATCATLFFILRKQYLRQERLRLKQMEEFQHEAQLLSRAKPEDRESLKS 300
Qy 301 ACVVCLSSFKSCVFLGCHVCSCTCYRALPEPKKPCICROAITRVIPLVNS 352
Db 301 ACVVCLSSFKSCVFLGCHVCSCTCYRALPEPKKPCICROAITRVIPLVNS 352

RESULT 4

US-10-315-664-105
; Sequence 105, Application US/10315664
; Publication No. US20030203377A1
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.
; APPLICANT: Bougueleret, L.
; APPLICANT: Jobert, S.
; TITLE OF INVENTION: Complementary DNA's Encoding Proteins with Signal
; FILE REFERENCE: Peptides
; CURRENT APPLICATION NUMBER: US/10/315.664
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US/09/599,360
; PRIOR FILING DATE: 2000-06-21
; PRIOR APPLICATION NUMBER: 60/113,686
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/141,032
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/469,099
; PRIOR FILING DATE: 1999-12-21
; NUMBER OF SEQ ID NOS: 123
; SOFTWARE: Patent.pm
; SEQ ID NO 105
; LENGTH: 352
; TYPE: PRT
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: SIGNAL
; LOCATION: -23...-1
US-10-315-664-105

Query Match 100.0%; Score 1831; DB 14; Length 352;
Best Local Similarity 100.0%; Pred. No. 1.6e-162;
Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MESGGRPSLCQFILLGTTTSVVTAALYSYVRQKARVSQELKGAKKVHLGEDLKSILSEAPG 60
Db 1 MESGGRPSLCQFILLGTTTSVVTAALYSYVRQKARVSQELKGAKKVHLGEDLKSILSEAPG 60
Qy 61 KCVPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLOEHKMWNRTHLWNCDSKIIHQ 120
Db 61 KCVPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLOEHKMWNRTHLWNCDSKIIHQ 120
Qy 121 TTTVPFDLVPHEDGVDVAVRVLPKLDSDVLGLTVEYKFPSPISQSFDTDVIGHYISGERPK 180
Db 121 TTTVPFDLVPHEDGVDVAVRVLPKLDSDVLGLTVEYKFPSPISQSFDTDVIGHYISGERPK 180
Qy 181 GIQTEMLKVGATLTGVELVLDNNSVRLQPPKQGMYYLSSQDFDLSLQROESSVRLW 240
Db 181 GIQTEMLKVGATLTGVELVLDNNSVRLQPPKQGMYYLSSQDFDLSLQROESSVRLW 240
Qy 241 KVLALVGFATCATLFFILRKQYLRQERLRLKQMEEFQHEAQLLSRAKPEDRESLKS 300
Db 241 KVLALVGFATCATLFFILRKQYLRQERLRLKQMEEFQHEAQLLSRAKPEDRESLKS 300
Qy 301 ACVVCLSSFKSCVFLGCHVCSCTCYRALPEPKKPCICROAITRVIPLVNS 352
Db 301 ACVVCLSSFKSCVFLGCHVCSCTCYRALPEPKKPCICROAITRVIPLVNS 352

Db 301 ACVVCLSSFKSCVFLGCHVCSCTCYRALPEPKKPCICROAITRVIPLVNS 352

RESULT 5

US-10-221-625-25
; Sequence 25, Application US/10221625
; Publication No. US20040033942A1
; GENERAL INFORMATION:
; APPLICANT: INCYTE GENOMICS, INC.
; APPLICANT: HILLMAN, Jennifer L.
; APPLICANT: BAUGHN, Mariah R.
; APPLICANT: YUE, Henry
; APPLICANT: LAL, Preeti
; APPLICANT: LU, Dyoung Aina M.
; APPLICANT: PATTERSON, Chandra
; APPLICANT: AZIMZAI, Yalda
; APPLICANT: BANDMAN, Olga
; APPLICANT: TANG, Y. Tom
; APPLICANT: MATHUR, Preete
; APPLICANT: SHAH, Purvi
; APPLICANT: AU-YOUNG, Janice
; APPLICANT: REDDY, Roopa
; TITLE OF INVENTION: TRANSCRIPTION FACTORS
; FILE REFERENCE: PR-0761 PCT
; CURRENT APPLICATION NUMBER: US/10/221.625
; CURRENT FILING DATE: 2001-03-13
; NUMBER OF SEQ ID NOS: 214
; SOFTWARE: PERL Program
; SEQ ID NO 25
; LENGTH: 352
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Incyte ID No. US20040033942A1 1383473CD1
US-10-221-625-25

Query Match 100.0%; Score 1831; DB 15; Length 352;
Best Local Similarity 100.0%; Pred. No. 1.6e-162;
Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MESGGRPSLCQFILLGTTTSVVTAALYSYVRQKARVSQELKGAKKVHLGEDLKSILSEAPG 60
Db 1 MESGGRPSLCQFILLGTTTSVVTAALYSYVRQKARVSQELKGAKKVHLGEDLKSILSEAPG 60
Qy 61 KCVPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLOEHKMWNRTHLWNCDSKIIHQ 120
Db 61 KCVPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLOEHKMWNRTHLWNCDSKIIHQ 120
Qy 121 TTTVPFDLVPHEDGVDVAVRVLPKLDSDVLGLTVEYKFPSPISQSFDTDVIGHYISGERPK 180
Db 121 TTTVPFDLVPHEDGVDVAVRVLPKLDSDVLGLTVEYKFPSPISQSFDTDVIGHYISGERPK 180
Qy 181 GIQTEMLKVGATLTGVELVLDNNSVRLQPPKQGMYYLSSQDFDLSLQROESSVRLW 240
Db 181 GIQTEMLKVGATLTGVELVLDNNSVRLQPPKQGMYYLSSQDFDLSLQROESSVRLW 240
Qy 241 KVLALVGFATCATLFFILRKQYLRQERLRLKQMEEFQHEAQLLSRAKPEDRESLKS 300
Db 241 KVLALVGFATCATLFFILRKQYLRQERLRLKQMEEFQHEAQLLSRAKPEDRESLKS 300
Qy 301 ACVVCLSSFKSCVFLGCHVCSCTCYRALPEPKKPCICROAITRVIPLVNS 352
Db 301 ACVVCLSSFKSCVFLGCHVCSCTCYRALPEPKKPCICROAITRVIPLVNS 352

RESULT 6

US-10-169-395-92
; Sequence 92, Application US/10169395
; Publication No. US20040034192A1
; GENERAL INFORMATION:
; APPLICANT: KATO, Seishi
; APPLICANT: KIMURA, Tomoko

```
; TITLE OF INVENTION: HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING
; TITLE OF INVENTION: THESE PROTEINS
; FILE REFERENCE: 01997.015100.US
; CURRENT APPLICATION NUMBER: US/10/169,395
; CURRENT FILING DATE: 2002-11-29
; PRIOR APPLICATION NUMBER: JP 2000-585
; PRIOR FILING DATE: 2000-01-06
; PRIOR APPLICATION NUMBER: JP 2000-588
; PRIOR FILING DATE: 2000-01-06
; PRIOR APPLICATION NUMBER: JP 2000-2299
; PRIOR FILING DATE: 2000-01-11
; PRIOR APPLICATION NUMBER: JP 2000-26862
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: JP 2000-58367
; PRIOR FILING DATE: 2000-03-03
; PRIOR APPLICATION NUMBER: PCT/JP00/09359
; PRIOR FILING DATE: 2000-12-28
; NUMBER OF SEQ ID NOS: 150
; SEQ ID NO 92
; LENGTH: 352
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-169-395-92

Query Match 100.0%; Score 1831; DB 15; Length 352;
Best Local Similarity 100.0%; Pred. No. 1.6e-162;
Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVVHLGDLKSIILSEAPG 60
DB 1 MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVVHLGDLKSIILSEAPG 60
QY 61 KCVPYAVIEGAVRSVKETLNSQFVENCCKGVIOQLTLQEHKVMVNRTHLWDCSKIHHQ 120
DB 61 KCVPYAVIEGAVRSVKETLNSQFVENCCKGVIOQLTLQEHKVMVNRTHLWDCSKIHHQ 120
QY 121 TMTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLGVETVYKPHPSIQSFTDVIHGYISGERPK 180
DB 121 TMTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLGVETVYKPHPSIQSFTDVIHGYISGERPK 180
QY 181 GQOETEEMLVKVGATLTGVGELVDNNSVRLQPPKQMGQYLLSSQDFDSLQEQESSVRLW 240
DB 181 GQOETEEMLVKVGATLTGVGELVDNNSVRLQPPKQMGQYLLSSQDFDSLQEQESSVRLW 240
QY 241 KVLALVFGFATCATLFFILRKQYLQORERLRLKQOEFEQHEAQLLSRAKPEDRESLKS 300
DB 241 KVLALVFGFATCATLFFILRKQYLQORERLRLKQOEFEQHEAQLLSRAKPEDRESLKS 300
QY 301 ACVCLSSPKSCVFLECGHVCSTCYRALPEPKKPCICROAITRVIPLYS 352
DB 301 ACVCLSSPKSCVFLECGHVCSTCYRALPEPKKPCICROAITRVIPLYS 352

RESULT 7
US-10-617-217A-75
; Sequence 75, Application US/10617217A
; Publication No. US2004008196A1
; GENERAL INFORMATION:
; APPLICANT: MATSUDA, Akio et al.
; TITLE OF INVENTION: NF-KB ACTIVATING GENE
; FILE REFERENCE: 1254-0229P
; CURRENT APPLICATION NUMBER: US/10/617,217A
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: JP 2000-402288
; PRIOR FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: JP 2001-088912
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: JP 2001-254018
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: US 60/258,315
; PRIOR FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: US 60/278,640
; PRIOR FILING DATE: 2001-03-26
```

```
; PRIOR APPLICATION NUMBER: US 60/314,385
; PRIOR FILING DATE: 2001-08-24
; NUMBER OF SEQ ID NOS: 224
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 75
; LENGTH: 352
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-617-217A-75

Query Match 100.0%; Score 1831; DB 15; Length 352;
Best Local Similarity 100.0%; Pred. No. 1.6e-162;
Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVVHLGDLKSIILSEAPG 60
DB 1 MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVVHLGDLKSIILSEAPG 60
QY 61 KCVPYAVIEGAVRSVKETLNSQFVENCCKGVIOQLTLQEHKVMVNRTHLWDCSKIHHQ 120
DB 61 KCVPYAVIEGAVRSVKETLNSQFVENCCKGVIOQLTLQEHKVMVNRTHLWDCSKIHHQ 120
QY 121 TMTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLGVETVYKPHPSIQSFTDVIHGYISGERPK 180
DB 121 TMTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLGVETVYKPHPSIQSFTDVIHGYISGERPK 180
QY 181 GQOETEEMLVKVGATLTGVGELVDNNSVRLQPPKQMGQYLLSSQDFDSLQEQESSVRLW 240
DB 181 GQOETEEMLVKVGATLTGVGELVDNNSVRLQPPKQMGQYLLSSQDFDSLQEQESSVRLW 240
QY 241 KVLALVFGFATCATLFFILRKQYLQORERLRLKQOEFEQHEAQLLSRAKPEDRESLKS 300
DB 241 KVLALVFGFATCATLFFILRKQYLQORERLRLKQOEFEQHEAQLLSRAKPEDRESLKS 300
QY 301 ACVCLSSPKSCVFLECGHVCSTCYRALPEPKKPCICROAITRVIPLYS 352
DB 301 ACVCLSSPKSCVFLECGHVCSTCYRALPEPKKPCICROAITRVIPLYS 352

RESULT 8
US-10-024-298A-75
; Sequence 75, Application US/10024298A
; Publication No. US20040214167A9
; GENERAL INFORMATION:
; APPLICANT: ASAH KASEI KABUSHIKI KAISHA
; APPLICANT: AKIO MATSUDA
; APPLICANT: GOICHI HONDA
; APPLICANT: SHUJI MURAMATSU
; APPLICANT: YUKIKO NAGANO
; TITLE OF INVENTION: NF-K B Activating Gene
; FILE REFERENCE: 1254-0191P
; CURRENT APPLICATION NUMBER: US/10/024,298A
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 60/314,385
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: 60/278,641
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: 60/258,315
; PRIOR FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: JP254018/2001
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: JP0088912/2001
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: JP402288/2000
; PRIOR FILING DATE: 2000-12-28
; NUMBER OF SEQ ID NOS: 182
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 75
; LENGTH: 352
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-024-298A-75
```



```
Query Match      100.0%; Score 1831; DB 17; Length 352;
Best Local Similarity 100.0%; Pred. No. 1.6e-162;
Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESGGRPSLCQFILLGTTTSVTTAALYSYVRQKARVSQELKGAKVHLGEDLKSILSEAPG 60
DB 1 MESGGRPSLCQFILLGTTTSVTTAALYSYVRQKARVSQELKGAKVHLGEDLKSILSEAPG 60

QY 61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIOQLTLOEHKVMWNRTHLWDCSKIIHOR 120
DB 61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIOQLTLOEHKVMWNRTHLWDCSKIIHOR 120

QY 121 TNPVPDLVPHEDGVDVAVRVLKPLDSVDLGLTVEYKHPHSIQSFTDVIHYISGERPK 180
DB 121 TNPVPDLVPHEDGVDVAVRVLKPLDSVDLGLTVEYKHPHSIQSFTDVIHYISGERPK 180

QY 181 GIQTEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYLLSQDPSLLQROESSVRLW 240
DB 181 GIQTEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYLLSQDPSLLQROESSVRLW 240

QY 241 KVLALVFGFATCATLFFILRKQYLQORLRLKQMOEFQHEAQLLSRAKPEDRESLSKS 300
DB 241 KVLALVFGFATCATLFFILRKQYLQORLRLKQMOEFQHEAQLLSRAKPEDRESLSKS 300

QY 301 ACVCLSSFKSCVFLGCHVCSCTECYRALPEPKKPCICRQAITRVIPLYS 352
DB 301 ACVCLSSFKSCVFLGCHVCSCTECYRALPEPKKPCICRQAITRVIPLYS 352

RESULT 9
US-09-764-864-801
; Sequence 801, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; PRIOR FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 801
; LENGTH: 392
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (238)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-864-801

Query Match      99.7%; Score 1826; DB 9; Length 392;
Best Local Similarity 99.7%; Pred. No. 5.5e-162;
Matches 351; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MESGGRPSLCQFILLGTTTSVTTAALYSYVRQKARVSQELKGAKVHLGEDLKSILSEAPG 60
DB 41 MESGGRPSLCQFILLGTTTSVTTAALYSYVRQKARVSQELKGAKVHLGEDLKSILSEAPG 100

QY 61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIOQLTLOEHKVMWNRTHLWDCSKIIHOR 120
DB 101 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIOQLTLOEHKVMWNRTHLWDCSKIIHOR 160

QY 121 TNPVPDLVPHEDGVDVAVRVLKPLDSVDLGLTVEYKHPHSIQSFTDVIHYISGERPK 180
DB 161 TNPVPDLVPHEDGVDVAVRVLKPLDSVDLGLTVEYKHPHSIQSFTDVIHYISGERPK 220

QY 181 GIQTEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYLLSQDPSLLQROESSVRLW 240
DB 221 GIQTEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYLLSQDPSLLQROESSVRLW 280

QY 241 KVLALVFGFATCATLFFILRKQYLQORLRLKQMOEFQHEAQLLSRAKPEDRESLSKS 300
```

```
DB 281 KVLALVFGFATCATLFFILRKQYLQORLRLKQMOEFQHEAQLLSRAKPEDRESLSKS 340
QY 301 ACVCLSSFKSCVFLGCHVCSCTECYRALPEPKKPCICRQAITRVIPLYS 352
DB 341 ACVCLSSFKSCVFLGCHVCSCTECYRALPEPKKPCICRQAITRVIPLYS 392

RESULT 10
US-10-024-298A-73
; Sequence 73, Application US/10024298A
; Publication No. US20030143540A1
; GENERAL INFORMATION:
; APPLICANT: ASahi Kasei Kabushiki Kaisha
; APPLICANT: Akio Matsuda
; APPLICANT: Goichi Honda
; APPLICANT: Shuji Muramatsu
; APPLICANT: Yukiko Nagano
; TITLE OF INVENTION: NF-K B Activating Gene
; FILE REFERENCE: 1254-0191P
; CURRENT APPLICATION NUMBER: US/10/024,298A
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 60/314,385
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: 60/278,641
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: 60/258,315
; PRIOR FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: JP254018/2001
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: JP008912/2001
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: JP402288/2000
; NUMBER OF SEQ ID NOS: 182
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 73
; LENGTH: 352
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-024-298A-73

Query Match      99.6%; Score 1824; DB 14; Length 352;
Best Local Similarity 99.7%; Pred. No. 7.3e-162;
Matches 351; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MESGGRPSLCQFILLGTTTSVTTAALYSYVRQKARVSQELKGAKVHLGEDLKSILSEAPG 60
DB 1 MESGGRPSLCQFILLGTTTSVTTAALYSYVRQKARVSQELKGAKVHLGEDLKSILSEAPG 60

QY 61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIOQLTLOEHKVMWNRTHLWDCSKIIHOR 120
DB 61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIOQLTLOEHKVMWNRTHLWDCSKIIHOR 120

QY 121 TNPVPDLVPHEDGVDVAVRVLKPLDSVDLGLTVEYKHPHSIQSFTDVIHYISGERPK 180
DB 121 TNPVPDLVPHEDGVDVAVRVLKPLDSVDLGLTVEYKHPHSIQSFTDVIHYISGERPK 180

QY 181 GIQTEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYLLSQDPSLLQROESSVRLW 240
DB 181 GIQTEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYLLSQDPSLLQROESSVRLW 240

QY 241 KVLALVFGFATCATLFFILRKQYLQORLRLKQMOEFQHEAQLLSRAKPEDRESLSKS 300
DB 241 KVLALVFGFATCATLFFILRKQYLQORLRLKQMOEFQHEAQLLSRAKPEDRESLSKS 300

QY 301 ACVCLSSFKSCVFLGCHVCSCTECYRALPEPKKPCICRQAITRVIPLYS 352
DB 301 ACVCLSSFKSCVFLGCHVCSCTECYRALPEPKKPCICRQAITRVIPLYS 352

RESULT 11
US-10-042-211A-73
```

```
; Sequence 73, Application US/10042211A
; Publication No. US20030170719A1
; GENERAL INFORMATION:
; APPLICANT: MATSUDA, Akio et al.
; TITLE OF INVENTION: NFKB Activating Gene
; FILE REFERENCE: 1254-0192P
; CURRENT APPLICATION NUMBER: US/10/042,211A
; PRIOR FILING DATE: 2002-01-11
; PRIOR APPLICATION NUMBER: JP 2000-402288
; PRIOR FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: JP 2001-088912
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: JP 2001-254018
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: US 60/258,315
; PRIOR FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: US 60/278,640
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 60/314,385
; PRIOR FILING DATE: 2001-08-24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 73
; LENGTH: 352
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-042-211A-73

Query Match          99.6%; Score 1824; DB 14; Length 352;
Best Local Similarity 99.7%; Pred. No. 7.3e-162;
Matches 351; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MESGGPRLCQFILLGTTTSVVTAAALYSVYRQKARVSQELKGAKVHGLGDLKSLSEAPG 60
Db 1 MESGGPRLCQFILLGTTTSVVTAAALYSVYRQKARVSQELKGAKVHGLGDLKSLSEAPG 60
QY 61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKMWNRTHLWDCSKIIHOR 120
Db 61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKMWNRTHLWDCSKIIHOR 120
QY 121 TMTVPDLVPHEDGVAVRVLKPLDSVDLGLTETVYKPHPSIQSFDTDVIGHYISGERPK 180
Db 121 TMTVPDLVPHEDGVAVRVLKPLDSVDLGLTETVYKPHPSIQSFDTDVIGHYISGERPK 180
QY 181 GIQETEMLKVGATLTGCGELVDLNNSVRLQPPKQGMYYLSSQDFDLSLLQROESSVRLW 240
Db 181 GIQETEMLKVGATLTGCGELVDLNNSVRLQPPKQGMYYLSSQDFDLSLLQROESSVRLW 240
QY 241 KVLALVFGFATCATLFFILRKQYLQERLRLKQMOEFOEHEAQLLSRAKPEDRESLKS 300
Db 241 KVLALVFGFATCATLFFILRKQYLQERLRLKQMOEFOEHEAQLLSRAKPEDRESLKS 300
QY 301 ACVVCLSSPKSCVFLGCHVCSCTCYRALPEPKKPCICRQAITRVIPLVNS 352
Db 301 ACVVCLSSPKSCVFLGCHVCSCTCYRALPEPKKPCICRQAITRVIPLVNS 352

RESULT 12
US-10-617-217A-73
; Sequence 73, Application US/10617217A
; Publication No. US20040081986A1
; GENERAL INFORMATION:
; APPLICANT: MATSUDA, Akio et al.
; TITLE OF INVENTION: NF-KB ACTIVATING GENE
; FILE REFERENCE: 1254-0229P
; CURRENT APPLICATION NUMBER: US/10/617,217A
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: JP 2000-402288
; PRIOR FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: JP 2001-088912
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: JP 2001-254018
; PRIOR FILING DATE: 2001-08-24
```

```
; PRIOR APPLICATION NUMBER: US 60/258,315
; PRIOR FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: US 60/278,640
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 60/314,385
; PRIOR FILING DATE: 2001-08-24
; NUMBER OF SEQ ID NOS: 224
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 73
; LENGTH: 352
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-617-217A-73

Query Match          99.6%; Score 1824; DB 15; Length 352;
Best Local Similarity 99.7%; Pred. No. 7.3e-162;
Matches 351; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MESGGPRLCQFILLGTTTSVVTAAALYSVYRQKARVSQELKGAKVHGLGDLKSLSEAPG 60
Db 1 MESGGPRLCQFILLGTTTSVVTAAALYSVYRQKARVSQELKGAKVHGLGDLKSLSEAPG 60
QY 61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKMWNRTHLWDCSKIIHOR 120
Db 61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKMWNRTHLWDCSKIIHOR 120
QY 121 TMTVPDLVPHEDGVAVRVLKPLDSVDLGLTETVYKPHPSIQSFDTDVIGHYISGERPK 180
Db 121 TMTVPDLVPHEDGVAVRVLKPLDSVDLGLTETVYKPHPSIQSFDTDVIGHYISGERPK 180
QY 181 GIQETEMLKVGATLTGCGELVDLNNSVRLQPPKQGMYYLSSQDFDLSLLQROESSVRLW 240
Db 181 GIQETEMLKVGATLTGCGELVDLNNSVRLQPPKQGMYYLSSQDFDLSLLQROESSVRLW 240
QY 241 KVLALVFGFATCATLFFILRKQYLQERLRLKQMOEFOEHEAQLLSRAKPEDRESLKS 300
Db 241 KVLALVFGFATCATLFFILRKQYLQERLRLKQMOEFOEHEAQLLSRAKPEDRESLKS 300
QY 301 ACVVCLSSPKSCVFLGCHVCSCTCYRALPEPKKPCICRQAITRVIPLVNS 352
Db 301 ACVVCLSSPKSCVFLGCHVCSCTCYRALPEPKKPCICRQAITRVIPLVNS 352

RESULT 13
US-10-024-298A-73
; Sequence 73, Application US/10024298A
; Publication No. US20040214167A9
; GENERAL INFORMATION:
; APPLICANT: ASAH I KASEI KABUSHIKI KAISHA
; APPLICANT: AKIO MATSUDA
; APPLICANT: GOICHI HONDA
; APPLICANT: SHUJI MURAMATSU
; APPLICANT: YUKIKO NAGANO
; TITLE OF INVENTION: NF-K B Activating Gene
; FILE REFERENCE: 1254-0191P
; CURRENT APPLICATION NUMBER: US/10/024,298A
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 60/314,385
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: 60/278,641
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: 60/258,315
; PRIOR FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: JP254018/2001
; PRIOR FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: JP0088912/2001
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: JP402288/2000
; PRIOR FILING DATE: 2000-12-28
; NUMBER OF SEQ ID NOS: 182
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 73
; LENGTH: 352
```

```
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-024-298A-73

Query Match          99.6%; Score 1824; DB 17; Length 352;
Best Local Similarity 99.7%; Pred. No. 7.3e-162;
Matches 351; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MESGGRPSLCQFILLGTTSTVTAALSVYRKARVSOELKGAKKHGDLKSLSEAPG 60
Db 1 MESGGRPSLCQFILLGTTSTVTAALSVYRKARVSOELKGAKKHGDLKSLSEAPG 60
QY 61 KCPYAVIEGAVRSVKETLNSQFVENCQVIGIQLTLQEHKQVWNRTHLWDCSKLIHOR 120
Db 61 KCPYAVIEGAVRSVKETLNSQFVENCQVIGIQLTLQEHKQVWNRTHLWDCSKLIHOR 120
QY 121 TMTVPDLVPHEDGVAVRVLPKPLSDVGLGVTEVYKHPSTQSTFDDVIGHYISGERPK 180
Db 121 TMTVPDLVPHEDGVAVRVLPKPLSDVGLGVTEVYKHPSTQSTFDDVIGHYISGERPK 180
QY 181 GIQETEEMLVKGATLTGVELVDNNSVRLQPPKQGMQYLLSSQDFDSLQEQESSVRLW 240
Db 181 GIQETEEMLVKGATLTGVELVDNNSVRLQPPKQGMQYLLSSQDFDSLQEQESSVRLW 240
QY 241 KVLALVFGFATCATLFFILRKQYLRQERLRKQMOEEFQEHQAQLLSRAKPEDRESLKS 300
Db 241 KVLALVFGFATCATLFFILRKQYLRQERLRKQMOEEFQEHQAQLLSRAKPEDRESLKS 300
QY 301 ACVCLSSFSKCVFLECGHVCSTECYRALPPEPKKPCICRQAITRVIPLVNS 352
Db 301 ACVCLSSFSKCVFLECGHVCSTECYRALPPEPKKPCICRQAITRVIPLVNS 352

RESULT 14
US-09-764-864-1262
; Sequence 1262, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PT223
; CURRENT APPLICATION NUMBER: US/09/764,864
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 1792
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1262
; LENGTH: 174
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (117)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-864-1262

Query Match          49.2%; Score 901; DB 9; Length 174;
Best Local Similarity 99.4%; Pred. No. 6.7e-76;
Matches 173; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 179 PKGIQETEEMLVKGATLTGVELVDNNSVRLQPPKQGMQYLLSSQDFDSLQEQESSVR 238
Db 1 PKGIQETEEMLVKGATLTGVELVDNNSVRLQPPKQGMQYLLSSQDFDSLQEQESSVR 238
QY 239 LKVLALVFGFATCATLFFILRKQYLRQERLRKQMOEEFQEHQAQLLSRAKPEDRESL 298
Db 61 LKVLALVFGFATCATLFFILRKQYLRQERLRKQMOEEFQEHQAQLLSRAKPEDRESL 298
QY 299 KSACVCLSSFSKCVFLECGHVCSTECYRALPPEPKKPCICRQAITRVIPLVNS 352
Db 121 KSACVCLSSFSKCVFLECGHVCSTECYRALPPEPKKPCICRQAITRVIPLVNS 352
```

```
RESULT 15
US-10-264-237-2680
; Sequence 2680, Application US/10264237
; Publication No. US20040009491A1
; GENERAL INFORMATION:
; APPLICANT: Birse et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PA131PI
; CURRENT APPLICATION NUMBER: US/10/264,237
; CURRENT FILING DATE: 2002-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/16450
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: US 60/205,515
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 2876
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 2680
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MISC FEATURE
; LOCATION: (108)
; OTHER INFORMATION: Xaa equals any of the twenty naturally occurring L-amino acids
US-10-264-237-2680

Query Match          46.6%; Score 854; DB 15; Length 165;
Best Local Similarity 99.4%; Pred. No. 1.6e-71;
Matches 164; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 188 MLKVGATLTGVELVDNNSVRLQPPKQGMQYLLSSQDFDSLQEQESSVRLWKVLAIVF 247
Db 1 MLKVGATLTGVELVDNNSVRLQPPKQGMQYLLSSQDFDSLQEQESSVRLWKVLAIVF 247
QY 248 GFATCATLFFILRKQYLRQERLRKQMOEEFQEHQAQLLSRAKPEDRESLKSACVCLV 307
Db 61 GFATCATLFFILRKQYLRQERLRKQMOEEFQEHQAQLLSRAKPEDRESLKSACVCLV 307
QY 308 SPKSCVFLFCGHVCSTECYRALPPEPKKPCICRQAITRVIPLVNS 352
Db 121 SPKSCVFLFCGHVCSTECYRALPPEPKKPCICRQAITRVIPLVNS 352

Search completed: November 6, 2004, 17:53:27
Job time : 144 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 6, 2004, 17:24:18 ; Search time 155 Seconds

(without alignments)
814.663 Million cell updates/sec

Title: US-09-978-360A-437

Perfect score: 1831

Sequence: 1 MESSGRPSLCQFILLTTSV.....PKKPCICQATRIPLVNS 352

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 358729299 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_23Sep04.*

1: Geneseqp1980s.*

2: Geneseqp1990s.*

3: Geneseqp2000s.*

4: Geneseqp2001s.*

5: Geneseqp2002s.*

6: Geneseqp2003as.*

7: Geneseqp2003bs.*

8: Geneseqp2004s.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1831	100.0	352	3	AAB25794 Human sec
2	1831	100.0	352	4	AAB25794 Human pro
3	1831	100.0	352	4	ABE06602 Human pro
4	1831	100.0	352	4	ABE50174 Human tra
5	1831	100.0	352	5	ABE75380 Human sec
6	1831	100.0	352	5	ABP61461 Human NF-
7	1831	100.0	352	8	ABP97404 Novel hum
8	1826	99.7	392	4	ADP19181 Human sec
9	1826	99.7	392	6	ASU15848 Human nov
10	1824	99.6	352	5	ABU54917 Human nov
11	1818	99.3	352	4	ABP61460 Human NF-
12	1328.5	72.6	263	6	ABE94353 Human pro
13	901	49.2	174	4	ABJ38698 Human nuc
14	901	49.2	174	6	AAU16309 Human nov
15	854	46.6	165	5	ABU53378 Human nov
16	445	24.3	91	2	ABE90304 Human pol
17	442.5	24.2	338	4	ABY13137 Human sec
18	439	24.0	90	2	ABE57873 Drosophil
19	437	23.9	88	2	AAV11645 Human 5'
20	201	11.0	383	3	AAV11871 Human 5'
21	200	10.9	383	3	AAG32339 Arabidops
22	200	10.9	399	3	AAG10096 Arabidops
23	188.5	10.3	332	7	AAG10095 Arabidops
24	188.5	10.3	332	8	ADD25209 Fertility
25	187.5	10.2	242	3	ADN61224 Radish nu
					AAG32340 Arabidops

26	186.5	10.2	242	3	AAG10097 Arabidops
27	177	9.7	206	3	AAG32341 Arabidops
28	163	8.9	257	4	AAE10909 Human gen
29	163	8.9	372	3	AAE10909 Human gen
30	155.5	8.5	303	6	AAE56882 Human apo
31	155.5	8.5	696	6	AAE56882 Human apo
32	155.5	8.5	723	3	ADA54907 Human pro
33	155.5	8.5	723	3	ADA54907 Human pro
34	155.5	8.5	723	7	ADA54857 Human pro
35	153	8.4	275	3	ADA54857 Human pro
36	151	8.2	700	4	ABG32886 Human RIN
37	148.5	8.1	115	4	ABG32886 Human RIN
38	148.5	8.1	115	4	ABG32886 Human RIN
39	145.5	7.9	336	5	ABG32886 Human RIN
40	144.5	7.9	438	2	ABG32886 Human RIN
41	144.5	7.9	618	2	ABG32886 Human RIN
42	144.5	7.9	618	2	ABG32886 Human RIN
43	144.5	7.9	618	2	ABG32886 Human RIN
44	144.5	7.9	618	6	ABG32886 Human RIN
45	144.5	7.9	618	7	ABG32886 Human RIN

ALIGNMENTS

RESULT 1
AAB25794
ID AAB25794 standard; protein; 352 AA.

XX AC AAB25794;

XX DT 28-NOV-2000 (first entry)

XX DE Human secreted protein SEQ ID #106.

XX KW Human; secreted protein; forensic procedure; gene therapy;
XX KW Chromosome mapping; cancer; autoimmune disease; cardiovascular disorder;
XX KW Cystic fibrosis; hypothyroidism; immunological disorder; amyloidosis;
XX KW Brain disorder; skeletal muscle disorder; eye disorder; obesity;
XX KW Mitochondriopathy; diabetes; atherosclerosis; Alzheimer's disease;
XX KW Neurodegenerative disorder; graft rejection; dementia; hyperlipidaemia;
XX KW Septic shock; impotence.

XX OS Homo sapiens.

XX PN WO200037491-A2.

XX PD 29-JUN-2000.

XX PF 20-DEC-1999; 99WO-IB002058.

XX PR 22-DEC-1998; 98US-0113686P.

XX PR 25-JUN-1999; 99US-0141032P.

XX PA (GEST) GENSET.

XX PI Bougueleret L, Dumas J, Duclert A;

XX XX WPI; 2000-442637/38.

XX DR N-PSDB; AAA87756.

XX PT Polynucleotides and polypeptides encoding proteins with signal peptides,
XX PT useful in diagnostic, forensic, gene therapy and chromosome mapping
XX PT procedures.

XX PS Claim 9; Page 279-280; 306pp; English.

XX CC This sequence represents a human secreted protein amino acid sequence.
XX CC The invention relates to sequences AAA87725-A87774 which encode human
XX CC secreted proteins AAB25763-B25812. The proteins include signal peptides.
XX CC Included in the invention are a host cell containing one of the cDNA
XX CC sequences, and a purified antibody capable of binding to one of the
XX CC secreted proteins. Also contained in the invention are methods for

CC storing the sequence data on a computer system, and a method for
CC identifying features of the cDNA sequences using a computer programme.
CC The cDNAs are useful for expressing secreted proteins or fragments to
CC obtain antibodies capable of specifically binding to the secreted
CC proteins. The cDNAs may also be useful in diagnostic, forensic, gene
CC therapy and chromosome mapping procedures and may be used to design
CC expression vectors and secretion vectors. The proteins of the invention
CC may be used to treat diseases including cancer, autoimmune diseases,
CC cardiovascular disorders, cystic fibrosis, hypothyroidism, immunological
CC disorders, amyloidosis, brain disorders, skeletal muscle disorders, eye
CC disorders, obesity, mitochondrial cytopathies, diabetes, atherosclerosis,
CC neurodegenerative disorders, graft rejection, Alzheimer's disease,
CC dementia, hyperlipidaemia, septic shock and impotence
XX
SQ Sequence 352 AA;
Query Match 100.0%; Score 1831; DB 3; Length 352;
Best Local Similarity 100.0%; Pred. No. 1.2e-168;
Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MESGRPSLCQFILLGTTSSVTAALYSVYRKARVQSELKGAKVHGLGDLKSLSEAPG 60
Db 1 MESGRPSLCQFILLGTTSSVTAALYSVYRKARVQSELKGAKVHGLGDLKSLSEAPG 60
Qy 61 KCPYAVTEGAVRSVKETLNSQFVENCCKGVQRLTLQEHKVMWNRTHLWDCSKIHOR 120
Db 61 KCPYAVTEGAVRSVKETLNSQFVENCCKGVQRLTLQEHKVMWNRTHLWDCSKIHOR 120
Qy 121 TNPVFDLVPHEGDVDAVRVLPKLDSDGLGVETVYKFPSPISQFTDVIHYSGERPK 180
Db 121 TNPVFDLVPHEGDVDAVRVLPKLDSDGLGVETVYKFPSPISQFTDVIHYSGERPK 180
Qy 181 GIQTEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYILSSQDFSLQOQESSVRLW 240
Db 181 GIQTEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYILSSQDFSLQOQESSVRLW 240
Qy 241 KVALVFGFATCATLFFILRKQYLQERLRLKQOEFOEHEAQLLSRAKPEDRESLKS 300
Db 241 KVALVFGFATCATLFFILRKQYLQERLRLKQOEFOEHEAQLLSRAKPEDRESLKS 300
Qy 301 ACVCLSSFKSCVFLECGHVCSTCYRALPEPKKPCICRQAITRVIPLYS 352
Db 301 ACVCLSSFKSCVFLECGHVCSTCYRALPEPKKPCICRQAITRVIPLYS 352
RESULT 2
ID AAE06602
XX AAE06602
XX AC AAE06602;
XX DT 25-SEP-2001 (first entry)
XX DE Human protein having hydrophobic domain, HP10649.
XX KW Human; hydrophobic domain; gene therapy; nutritional supplement;
KW cell proliferation; immunomodulatory; autoimmune disorder; antimicrobial;
KW multiple sclerosis; rheumatoid arthritis; insulin-dependent diabetes;
KW haematopoiesis; tissue growth activity; Parkinson's disease; cytostatic;
KW Huntington's disease; Alzheimer's disease; chemotactic; chemokinetic;
KW haemostatic; thrombolytic; tumour growth inhibitor; anabolic;
KW contraceptive; antiinfertility; antiinflammatory.
XX OS Homo sapiens.
XX PN WO200149728-A2.
XX XX 12-JUL-2001.
XX XX 28-DEC-2000; 2000WO-JP009359.
XX XX 06-JAN-2000; 2000JP-00000585.
PR 06-JAN-2000; 2000JP-00000588.

PR 11-JAN-2000; 2000JP-00002299.
PR 03-FEB-2000; 2000JP-00026862.
PR 03-MAR-2000; 2000JP-00058367.
XX
PA (PROT-) PROTEGENE INC.
PA (SAGA) SAGAMI CHEM RES CENT.
XX
XX Kato S, Kimura T;
XX WPI; 2001-418355/44.
DR N-PSDB; AAD12597.
XX
XX Human proteins with hydrophobic domains and the nucleic acids encoding
XX them, useful for preventing diagnosing and treating e.g. cancer,
XX Alzheimer's and inflammation.
XX
XX Claim 1; Page 122; 563pp; English.
XX
XX The present sequence is human protein with hydrophobic domain, HP10649.
XX The polynucleotide and polypeptide of the invention may be used in the
XX prevention, diagnosis and treatment of diseases associated with
XX inappropriate polypeptide expression. The polynucleotides may be used to
XX produce the polypeptide, by inserting the nucleic acids into a host cell
XX and culturing the cell to express the protein. The polynucleotides and
XX its complementary sequences may also be used as DNA probes in diagnostic
XX assays and also used in gene therapy. The polypeptides may also be used
XX as antigens in the production of antibodies and in assays to identify
XX modulators of polypeptide expression and activity. The polypeptides and
XX nucleic acids may be used as nutritional supplements, to modulate
XX cytokine and cell proliferation activity, to modulate immune stimulation
XX or suppression (e.g. for the treatment of microbial infections and
XX autoimmune disorders such as multiple sclerosis, rheumatoid arthritis and
XX insulin-dependent diabetes), to modulate haematopoiesis, to modulate
XX tissue growth activity (e.g. for the treatment of Parkinson's disease,
XX Huntington's disease and Alzheimer's disease), to modulate activin and
XX inhibin activity (e.g. for controlling fertility), to modulate
XX chemotactic and chemokinetic activity, to modulate haemostatic and
XX thrombolytic activity, to modulate receptor ligand activity, to modulate
XX inflammation and to inhibit tumour growth
XX
SQ Sequence 352 AA;
Query Match 100.0%; Score 1831; DB 4; Length 352;
Best Local Similarity 100.0%; Pred. No. 1.2e-168;
Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MESGRPSLCQFILLGTTSSVTAALYSVYRKARVQSELKGAKVHGLGDLKSLSEAPG 60
Db 1 MESGRPSLCQFILLGTTSSVTAALYSVYRKARVQSELKGAKVHGLGDLKSLSEAPG 60
Qy 61 KCPYAVTEGAVRSVKETLNSQFVENCCKGVQRLTLQEHKVMWNRTHLWDCSKIHOR 120
Db 61 KCPYAVTEGAVRSVKETLNSQFVENCCKGVQRLTLQEHKVMWNRTHLWDCSKIHOR 120
Qy 121 TNPVFDLVPHEGDVDAVRVLPKLDSDGLGVETVYKFPSPISQFTDVIHYSGERPK 180
Db 121 TNPVFDLVPHEGDVDAVRVLPKLDSDGLGVETVYKFPSPISQFTDVIHYSGERPK 180
Qy 181 GIQTEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYILSSQDFSLQOQESSVRLW 240
Db 181 GIQTEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYILSSQDFSLQOQESSVRLW 240
Qy 241 KVALVFGFATCATLFFILRKQYLQERLRLKQOEFOEHEAQLLSRAKPEDRESLKS 300
Db 241 KVALVFGFATCATLFFILRKQYLQERLRLKQOEFOEHEAQLLSRAKPEDRESLKS 300
Qy 301 ACVCLSSFKSCVFLECGHVCSTCYRALPEPKKPCICRQAITRVIPLYS 352
Db 301 ACVCLSSFKSCVFLECGHVCSTCYRALPEPKKPCICRQAITRVIPLYS 352
RESULT 3
ABB50174

ID ABB50174 standard; protein; 352 AA.
 AC ABB50174;
 DT 05-FEB-2002 (first entry)
 DE Human transcription factor TRFX-25.
 DE Human; transcription factor; TRFX; cell proliferative disease;
 KW autoimmune disease; inflammation; neurological disease;
 KW developmental disorder; cancer; AIDS; infection; cytostatic; anti-HIV;
 KW neuroprotective; antiinflammatory; gene therapy.
 OS Homo sapiens.
 XX WO200172777-A2.
 XX 04-OCT-2001.
 XX 13-MAR-2001; 2001WO-US008117.
 XX 13-MAR-2000; 2000US-0188986P.
 XX (INCY-) INCYTE GENOMICS INC.
 XX Hillman JL, Baughn MR, Yue H, Lal P, Lu DAM, Patterson C;
 PI Azimzai Y, Bandman O, Tang YT, Mathur P, Shah P, Au-Young J;
 PI Reddy R;
 XX WPI: 2001-570896/64.
 DR N-PSDB; ABA82998.
 XX Novel transcription factor polypeptides, used to treat diseases
 PT associated with altered activity and expression of TRFX, and to screen
 PT for agents capable of modulating its activity.
 XX Claim 1; Page 168-169; 327pp; English.
 CC The present sequence is the protein sequence for a human transcription
 CC factor. The transcription factor and its coding sequence are useful in
 CC the diagnosis, treatment and prevention of diseases associated with
 CC altered expression of the transcription factor e.g. cell proliferative,
 CC autoimmune/inflammatory, neurological and developmental disorders. A
 CC number of specific disorders/diseases are given in the specification,
 CC including: arteriosclerosis, cirrhosis, hepatitis, cancers, AIDS,
 CC allergies, anaemia, asthma, autoimmune thyroiditis, bronchitis, atopic
 CC dermatitis, diabetes mellitus, emphysema, Goodpasture's syndrome, gout,
 CC Grave's disease, multiple sclerosis, osteoarthritis, pancreatitis,
 CC psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative
 CC colitis, uveitis, Alzheimer's disease, Huntington's disease, Parkinson's
 CC disease, stroke, and viral, bacterial, fungal and protozoal infections
 XX SQ Sequence 352 AA;
 Query Match 100.0%; Score 1831; DB 4; Length 352;
 Best Local Similarity 100.0%; Pred. No. 1.2e-168;
 Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MESGGRSLCQFILLGTTTAAALYSYVRQKARVSQELGAKKXVHLGDLKSLSEAPG 60
 DB 1 MESGGRSLCQFILLGTTTAAALYSYVRQKARVSQELGAKKXVHLGDLKSLSEAPG 60
 QY 61 KCPYAVIEGAVRSVKETLNSQFVENCXGVIQRLTLOEHKQVWNRTHLWNCDSKIIHQ 120
 DB 61 KCPYAVIEGAVRSVKETLNSQFVENCXGVIQRLTLOEHKQVWNRTHLWNCDSKIIHQ 120
 QY 121 TMTVPDLVPHEDGVAVRVLPKLDSDGLGVYKFKHPSIQSFDDVIGHYISGERPK 180
 DB 121 TMTVPDLVPHEDGVAVRVLPKLDSDGLGVYKFKHPSIQSFDDVIGHYISGERPK 180
 QY 181 GIQTEEMLVKVGATLTGVELVLDNNSVRLQPPKQGMQYLLSQDFDLSLQRESSVRLW 240
 DB 181 GIQTEEMLVKVGATLTGVELVLDNNSVRLQPPKQGMQYLLSQDFDLSLQRESSVRLW 240

QY 241 KVLALVFGFATCATLFFILRKQYLQERLRLKQMOEEFOEHAQLLSRAKPEDRESLKS 300
 DB 241 KVLALVFGFATCATLFFILRKQYLQERLRLKQMOEEFOEHAQLLSRAKPEDRESLKS 300
 QY 301 ACVVCLSSPKSCVFLGCGHVCSTECYRALPEPKKCPICRQAITRVIPLYNS 352
 DB 301 ACVVCLSSPKSCVFLGCGHVCSTECYRALPEPKKCPICRQAITRVIPLYNS 352
 RESULT 4
 AAB75380
 ID AAB75380 standard; protein; 352 AA.
 XX AAB75380;
 XX 05-APR-2001 (first entry)
 DT Human secreted protein #39.
 DE Human secreted protein #39.
 DE Secreted protein; prevention; treatment; diagnosis; disease; infection.
 OS Homo sapiens.
 XX WO200100806-A2.
 XX 04-JAN-2001.
 XX 21-JUN-2000; 2000WO-IB000951.
 XX 25-JUN-1999; 99US-0141032P.
 XX 21-DEC-1999; 99US-00469099.
 XX (GEST) GENSET.
 PI Dumas Milne Edwards J, Bougueleret L, Jobert S;
 XX WPI: 2001-071487/08.
 CC 49 Secreted proteins and the nucleic acids encoding them, useful in gene
 CC therapy and for detecting similar sequences in samples.
 CC Claim 10; Page 299-300; 307pp; English.
 CC The present invention relates to 49 secreted proteins and the cDNAs
 CC encoding them. The protein and nucleic acids may be used in the
 CC prevention, treatment and diagnosis of diseases associated with
 CC inappropriate protein expression
 XX SQ Sequence 352 AA;
 Query Match 100.0%; Score 1831; DB 4; Length 352;
 Best Local Similarity 100.0%; Pred. No. 1.2e-168;
 Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MESGGRSLCQFILLGTTTAAALYSYVRQKARVSQELGAKKXVHLGDLKSLSEAPG 60
 DB 1 MESGGRSLCQFILLGTTTAAALYSYVRQKARVSQELGAKKXVHLGDLKSLSEAPG 60
 QY 61 KCPYAVIEGAVRSVKETLNSQFVENCXGVIQRLTLOEHKQVWNRTHLWNCDSKIIHQ 120
 DB 61 KCPYAVIEGAVRSVKETLNSQFVENCXGVIQRLTLOEHKQVWNRTHLWNCDSKIIHQ 120
 QY 121 TMTVPDLVPHEDGVAVRVLPKLDSDGLGVYKFKHPSIQSFDDVIGHYISGERPK 180
 DB 121 TMTVPDLVPHEDGVAVRVLPKLDSDGLGVYKFKHPSIQSFDDVIGHYISGERPK 180
 QY 181 GIQTEEMLVKVGATLTGVELVLDNNSVRLQPPKQGMQYLLSQDFDLSLQRESSVRLW 240
 DB 181 GIQTEEMLVKVGATLTGVELVLDNNSVRLQPPKQGMQYLLSQDFDLSLQRESSVRLW 240
 QY 241 KVLALVFGFATCATLFFILRKQYLQERLRLKQMOEEFOEHAQLLSRAKPEDRESLKS 300

```
Db 241 KVLALVFGFATCATLFFILRKQYLQORERLRLKQWQEFQHEAQLLSRAKPEDRESLKS 300
ABP61461
Qy 301 ACVVCLSSFKSCVFLECHGVCSCTEYRALPEPKKPCICROAIRVPIPLNS 352
Db 301 ACVVCLSSFKSCVFLECHGVCSCTEYRALPEPKKPCICROAIRVPIPLNS 352
RESULT 5
ID ABP61461 standard; protein; 352 AA.
XX AC ABP61461;
XX DT 30-SEP-2002 (first entry)
XX DE Human NF-KB activating protein SEQ ID NO 75.
XX KW Human; NF-kB; nuclear factor kappa B; mouse; antiinflammatory;
KW immunomodulator; cytostatic; antiinfective; osteopathic; nootropic;
KW neuroprotective; anti-HIV; autoimmune disease; cancer; infection;
XX bone disease; AIDS; neurodegenerative disease; ischaemic disorder.
XX OS Homo sapiens.
XX PN WO200253737-A1.
XX PD 11-JUL-2002.
XX PF 25-DEC-2001; 2001WO-JP011389.
XX PR 28-DEC-2000; 2000JP-00402288.
XX PR 26-MAR-2001; 2001JP-00088912.
XX PR 24-AUG-2001; 2001JP-00254018.
XX PA (ASAH ) ASahi KASEI KOGYO KK.
XX PI Matsuda A, Honda G, Muramatsu S, Nagano Y;
XX WPI; 2002-583617/62.
XX N-PSDB; ABQ91949.
XX NP-approximatelykB activating gene and expressed protein, applicable in
PT diagnosis and screening inhibitors or promoters to control excessive
PT activation or inhibition for treating e.g. inflammations, autoimmune
PT diseases and cancer.
XX Claim 1; Page 349-352; 841pp; Japanese.
XX The invention relates to a purified protein (I), comprising one of 90
CC fully defined sequences (ABP61424-ABP61513) or a protein based on any of
CC the sequences but with some amino acids deleted, substituted or added and
CC with a NF-kB (nuclear factor kappa B) activating effect. The protein and
CC encoding gene (ABQ91912-ABQ92001) are useful in diagnosis and screening
CC inhibitors or promoters to control excessive activation or inhibition
CC for treating e.g. inflammations, autoimmune diseases, cancers,
CC infections, bone diseases, AIDS, neurodegenerative diseases or ischaemic
CC disorders
XX Sequence 352 AA;
Query Match 100.0%; Score 1831; DB 5; Length 352;
Best Local Similarity 100.0%; Pred. No. 1.2e-168;
Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MESGGRSLCQFILLGTTTSVVTALYSVYRQKARVSQELKGAKKVLHGEDLKSILSPAPG 60
Db 1 MESGGRSLCQFILLGTTTSVVTALYSVYRQKARVSQELKGAKKVLHGEDLKSILSPAPG 60
Qy 61 KCVPYAVIEGAVRSVKETLNSQFVENCKGVIQRLTLQEHKQVWNRTHLWNCDSKIIHOR 120
Db 61 KCVPYAVIEGAVRSVKETLNSQFVENCKGVIQRLTLQEHKQVWNRTHLWNCDSKIIHOR 120
Qy 121 TNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLTETVEKFPESIQSFTDVIHGYSGERPK 180
121 TNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLTETVEKFPESIQSFTDVIHGYSGERPK 180
Db 121 TNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLTETVEKFPESIQSFTDVIHGYSGERPK 180
Qy 181 GIQTEEMLKVGATLTGVELVLDDNNSVRLOPPKQGMQYLLSSODFSLQROESSVRLW 240
181 GIQTEEMLKVGATLTGVELVLDDNNSVRLOPPKQGMQYLLSSODFSLQROESSVRLW 240
Qy 181 GIQTEEMLKVGATLTGVELVLDDNNSVRLOPPKQGMQYLLSSODFSLQROESSVRLW 240
241 KVLALVFGFATCATLFFILRKQYLQORERLRLKQWQEFQHEAQLLSRAKPEDRESLKS 300
241 KVLALVFGFATCATLFFILRKQYLQORERLRLKQWQEFQHEAQLLSRAKPEDRESLKS 300
Qy 301 ACVVCLSSFKSCVFLECHGVCSCTEYRALPEPKKPCICROAIRVPIPLNS 352
Db 301 ACVVCLSSFKSCVFLECHGVCSCTEYRALPEPKKPCICROAIRVPIPLNS 352
RESULT 6
ABP97404
ID ABB97404 standard; protein; 352 AA.
XX AC ABB97404;
XX DT 27-JUN-2002 (first entry)
XX DE Novel human protein SEQ ID NO: 672.
XX KW Human; antianaemic; vulnary; antiinflammatory; immunomodulator;
KW antifertility; cerebroprotective; cytostatic; rheumatic; gene therapy;
KW neuroprotective; antiparkinsonian; protein therapy; EST;
XX expressed sequence tag.
XX OS Homo sapiens.
XX PN WO200222660-A2.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US026015.
XX PR 11-SEP-2000; 2000US-00659671.
XX (HYSE-) HYSEQ INC.
XX Tang YT, Liu C, Zhou P, Asundi V, Zhang J, Zhao QA, Ren F;
XX Xue AJ, Yang Y, Wehrman T, Drmanac RT;
XX WPI; 2002-292408/33.
XX N-PSDB; ABN32590.
XX An isolated polynucleotide for treating diseases associated with its
XX encoded polypeptide such as cancer and multiple sclerosis.
XX Claim 20; SEQ ID NO 672; 509pp; English.
XX The present invention provides the protein and coding sequences of 444
XX novel human proteins. These were isolated from expressed sequences tags
XX (ESTs). They can be used to stimulate cell growth, to regulate
XX haematopoiesis e.g. to treat aplastic anaemia, to help tissue regrowth
XX e.g. in burn treatment, to regulate the immune system e.g. to treat
XX multiple sclerosis, to regulate activin or inhibit e.g. to treat
XX infertility, to regulate haemostasis or thrombolysis e.g. to treat stroke
XX and cancer, to screen for drugs, to treat inflammatory conditions e.g.
XX rheumatoid arthritis, and to treat nervous system disorders e.g.
XX Parkinson's disease. The present sequence is a protein of the invention
XX Sequence 352 AA;
Query Match 100.0%; Score 1831; DB 5; Length 352;
Best Local Similarity 100.0%; Pred. No. 1.2e-168;
Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MESGGRSLCQFILLGTTTSVVTALYSVYRQKARVSQELKGAKKVLHGEDLKSILSPAPG 60
121 TNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLTETVEKFPESIQSFTDVIHGYSGERPK 180
```

Db 1 MESGRPSLCQFILLGTTSVVTAALYSVYRKARVSQELKGAKVHGLGDLKSLSEAPG 60
QY 61 KCVPAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKVMWNRTHLWDCSKIIHOR 120
Db 61 KCVPAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKVMWNRTHLWDCSKIIHOR 120
QY 121 TMTVPFDLPVPHEDGVDVAVRVLKPLDSVDLGLTGVYVEKFPSTQSFDTVIGHYISGERPK 180
Db 121 TMTVPFDLPVPHEDGVDVAVRVLKPLDSVDLGLTGVYVEKFPSTQSFDTVIGHYISGERPK 180
QY 181 GQETEEMLKVGATLTGVELVLDNNSVRLQPPKQGMQYLLSSQDFDLSLLQRESSVRLW 240
Db 181 GQETEEMLKVGATLTGVELVLDNNSVRLQPPKQGMQYLLSSQDFDLSLLQRESSVRLW 240
QY 241 KVLALVFGFATCATLFFILRKQYLQORERLRLKQOEERFQHEAQLLSRAKPEDRESLKS 300
Db 241 KVLALVFGFATCATLFFILRKQYLQORERLRLKQOEERFQHEAQLLSRAKPEDRESLKS 300
QY 301 ACVCLSSFKSCVFLGCHGVCSTCYRALPEPKKPCICROAITRVIPLVNS 352
Db 301 ACVCLSSFKSCVFLGCHGVCSTCYRALPEPKKPCICROAITRVIPLVNS 352

RESULT 7

ADP19181
ID ADP19181 standard; protein; 352 AA.

AC ADP19181;

XX

DT 26-AUG-2004 (first entry)

DE Human secreted polypeptide #32.

KW Human; secreted protein; genetic disease.

XX Homo sapiens.

OS US2004110939-A1.

XX 10-JUN-2004.

XX 15-OCT-2001; 2001US-00978360.

XX 17-DEC-1998; 98WO-IB002122.

XX 09-FEB-1999; 99WO-IB000282.

XX 21-JUN-2000; 2000WO-IB000951.

XX 15-SEP-2000; 2000US-00663600.

XX (GIST) GENSET SA.

XX Dumas Milne Edwards J, Bougueleret L, Jobert S, Clusel C;
PI Duclert A;

XX WPI; 2004-440404/41.

XX N-PSDB; ADP18776.

PT New isolated polynucleotide encoding secreted polypeptide, useful for
PT gene therapy, or in diagnostic procedures to identify individuals having
PT genetic diseases resulting from abnormal expression of the genes.

XX Claim 2; SEQ ID NO 437; 113pp; English.

XX The invention relates to human cDNA sequences that encode human secreted
CC proteins. The invention also relates to an antibody that specifically
CC binds to a polypeptide of the invention and a method of binding the
CC polypeptide to an antibody. The polynucleotides are useful for expressing
CC the entire secreted proteins which they encode and for distinguishing
CC human tissues and cells from non-human tissues and cells, and for
CC distinguishing between human tissues and cells that do or do not express
CC the polynucleotides comprising the cDNAs. The polynucleotides and
CC polypeptides are useful in forensic procedures or diagnostic procedures
CC to identify individuals with genetic diseases resulting from abnormal
CC expression of the genes corresponding to the cDNAs. The sequences are

CC also useful in gene therapy to control or treat genetic diseases. This
CC sequence represents a human secreted polypeptide of the invention. Note:
CC the sequence data for this patent did not form part of the printed
CC specification but was obtained in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html.

XX Sequence 352 AA;

Query Match 100.0%; Score 1831; DB 8; Length 352;
Best Local Similarity 100.0%; Pred. No. 1.2e-168;

Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MESGRPSLCQFILLGTTSVVTAALYSVYRKARVSQELKGAKVHGLGDLKSLSEAPG 60

Db 1 MESGRPSLCQFILLGTTSVVTAALYSVYRKARVSQELKGAKVHGLGDLKSLSEAPG 60

QY 61 KCVPAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKVMWNRTHLWDCSKIIHOR 120

Db 61 KCVPAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKVMWNRTHLWDCSKIIHOR 120

QY 121 TMTVPFDLPVPHEDGVDVAVRVLKPLDSVDLGLTGVYVEKFPSTQSFDTVIGHYISGERPK 180

Db 121 TMTVPFDLPVPHEDGVDVAVRVLKPLDSVDLGLTGVYVEKFPSTQSFDTVIGHYISGERPK 180

QY 181 GQETEEMLKVGATLTGVELVLDNNSVRLQPPKQGMQYLLSSQDFDLSLLQRESSVRLW 240

Db 181 GQETEEMLKVGATLTGVELVLDNNSVRLQPPKQGMQYLLSSQDFDLSLLQRESSVRLW 240

QY 241 KVLALVFGFATCATLFFILRKQYLQORERLRLKQOEERFQHEAQLLSRAKPEDRESLKS 300

Db 241 KVLALVFGFATCATLFFILRKQYLQORERLRLKQOEERFQHEAQLLSRAKPEDRESLKS 300

QY 301 ACVCLSSFKSCVFLGCHGVCSTCYRALPEPKKPCICROAITRVIPLVNS 352

Db 301 ACVCLSSFKSCVFLGCHGVCSTCYRALPEPKKPCICROAITRVIPLVNS 352

RESULT 8

AAU15848
ID AAU15848 standard; protein; 392 AA.

XX AAU15848;

XX 07-NOV-2001 (first entry)

DE Human novel secreted protein, Seq ID 801.

KW Human; immunosuppressive; antiarthritic; antirheumatic; cytostatic;
KW cardiant; vasotropic; cerebroprotective; neurotropic; neuroprotective;
KW antibacterial; virucide; fungicide; opthalmological; vulnerary;
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; skin ageing; food additive;
KW preservative; antiproliferative.

XX Homo sapiens.

OS WO200155322-A2.

XX 02-AUG-2001.

XX 17-JAN-2001; 2001WO-US001341.

XX 31-JAN-2000; 2000US-0179065P.

XX 04-FEB-2000; 2000US-0180628P.

XX 24-FEB-2000; 2000US-0184664P.

XX 02-MAR-2000; 2000US-0186350P.

XX 16-MAR-2000; 2000US-0189874P.

XX 17-MAR-2000; 2000US-0190076P.

XX 18-APR-2000; 2000US-0198123P.

XX 19-MAY-2000; 2000US-0205515P.

PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 08-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234597P.
PR 25-SEP-2000; 2000US-0234598P.
PR 26-SEP-2000; 2000US-0234548P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.

PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.

XX (HUMA-) HUMAN GENOME SCI INC.
PA

XX Rosen CA, Barash SC, Ruben SM;

XX WPI; 2001-488783/53.

XX N-PSDB; AAS25835.

XX New nucleic acid molecules encoding 461 human secreted proteins for
PT diagnosing, preventing, treating or ameliorating medical conditions and
PT used as food additives or preservatives.

XX Claim 11; SEQ ID NO 801; 980pp; English.

XX The invention relates to isolated nucleic acid molecules and their
CC encoded secreted proteins. The nucleic acids and proteins are used to
CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used

CC in diagnosing a pathological condition or susceptibility to a
CC pathological condition. Antibodies to the proteins can also be used in
CC alleviating symptoms associated with the disorders and in diagnostic
CC immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays
CC (ELISA). Disorders which are diagnosed or treated include autoimmune
CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
CC arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,
CC nervous system disorders e.g. Alzheimer's disease, infections caused by
CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection,
CC and many other disorders listed in the specification. The polypeptides
CC can also be used to aid wound healing and epithelial cell proliferation,
CC to prevent skin aging due to sunburn, to maintain organs before
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. The present
CC sequence represents a novel secreted protein of the invention. Note: The
CC sequence data for this patent did not form part of the printed

Query Match 99.7%; Score 1826; DB 4; Length 392;
Best Local Similarity 99.7%; Pred. No. 4.2e-168;
Matches 351; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MESSGRPSLCOFILLGTTSSVTAALYSVYRKARVSQELKGAKVHLGDLKSIILSEAPG 60
Db 41 MESSGRPSLCOFILLGTTSSVTAALYSVYRKARVSQELKGAKVHLGDLKSIILSEAPG 100
QY 61 KCVPYAVIEGAVRSVKETLNSQFVENCCKGVQLRTLQEHKVMWNRTTHLWDCSKIIHQ 120
Db 101 KCVPYAVIEGAVRSVKETLNSQFVENCCKGVQLRTLQEHKVMWNRTTHLWDCSKIIHQ 160
QY 121 TMTVPFDLVPHEDGVDAVRVLKPLDSVDLGLTVEYKPHSIQSFDTVIGHYISGERPK 180
Db 161 TMTVPFDLVPHEDGVDAVRVLKPLDSVDLGLTVEYKPHSIQSFDTVIGHYISGERPK 220
QY 181 GIOETEEMKVGATLTGVEGLVDNNSVRLQPKQMGQYVYSSQDFDLSLQROESSVRLM 240
Db 221 GIOETEEMKVGATLTGVEGLVDNNSVRLQPKQMGQYVYSSQDFDLSLQROESSVRLM 280
QY 241 KVLALVFGFATCATLFFILRKQYLQRLKQRLKQOEFEQHEAQLLSRAKPEDRESLKS 300
Db 281 KVLALVFGFATCATLFFILRKQYLQRLKQRLKQOEFEQHEAQLLSRAKPEDRESLKS 340
QY 301 ACVCLSSFKSCVPLECGHVCSTCYRALPEPKKPCICROAITRVIPLVNS 352
Db 341 ACVCLSSFKSCVPLECGHVCSTCYRALPEPKKPCICROAITRVIPLVNS 392

RESULT 9
ABUS4917
ID ABUS4917 standard; protein; 392 AA.

AC ABUS4917;

DT 18-MAR-2003 (first entry)

DE Human novel polypeptide #4.

KW Human; neural disorder; immune system disorder; renal disorder;
KW muscular disorder; respiratory disease; reproductive disorder;
KW gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;
KW hyperproliferative disorder; inflammatory disease; allergic reaction;
KW blood related disorder; cancer; immunosuppressive; antiinflammatory;
KW cardiovascular; nephrotropic; cytostatic; antiallergic; thrombolytic;
KW haemostatic; antiarteriosclerotic.

OS Homo sapiens.

PN US2002132753-A1.

XX 19-SEP-2002..

XX 17-JAN-2001; 2001US-00764864.
PF 31-JAN-2000; 2000US-0179065P.
XX 04-FEB-2000; 2000US-0180628P.
PR 28-JUN-2000; 2000US-0214886P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 22-AUG-2000; 2000US-0226868P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 08-SEP-2000; 2000US-0231413P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 27-SEP-2000; 2000US-0235834P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241809P.
PR 01-NOV-2000; 2000US-0244617P.
PR 17-NOV-2000; 2000US-0249299P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
XX (ROSE/) ROSEN C A.
PA (RUBE/) RUBEN S M.
PA (BARA/) BARASH S C.
XX Rosen CA, Ruben SM, Barash SC;
PI WPI, 2003-147444/14.
XX N-PSDB; ABX73176.
XX New polypeptides and nucleic acids, useful in gene therapy for treating,
XX inhibiting or preventing e.g. neural, immune system, muscular,
XX respiratory, reproductive, gastrointestinal, pulmonary, cardiovascular or
XX renal disorders.
XX Claim 11; SEQ ID NO 801; 402pp; English.
PS The invention relates to human novel polypeptides and their associated
XX polynucleotides. The polypeptides and polynucleotides are useful in gene
XX therapy for treating, inhibiting or preventing neural disorders, immune

CC system disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis
CC and multiple sclerosis), muscular disorders, respiratory diseases (e.g.
CC nasal vestibulitis, nasal polyps and sinusitis), reproductive disorders,
CC gastrointestinal disorders, pulmonary disorders, cardiovascular disorders
CC (e.g. congenital heart defects, Ebstein's anomaly and hypoplastic left
CC heart syndrome), renal disorders (e.g. acute kidney failure and end-stage
CC renal disease), hyperproliferative disorders (e.g. Hodgkin's disease and
CC leukaemia), inflammatory diseases (e.g. septic shock, bursitis and
CC appendicitis), allergic reactions and conditions (e.g. asthma), blood
CC related disorders (e.g. thrombosis, atherosclerosis and myocardial
CC infarction) and cancerous diseases. Sequences ABU54914-ABU55699 and
CC ABU55748 represent human novel polypeptides of the invention
XX
SQ Sequence 392 AA;

Query Match 99.7%; Score 1826; DB 6; Length 392;
Best Local Similarity 99.7%; Pred. No. 4.2e-168;
Matches 351; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MESGGRPSCQFILLGTTTSVTAALYSVYRQKARVSQELKGAKVHLGDLKSLSEAPG 60
DB 41 MESGGRPSCQFILLGTTTSVTAALYSVYRQKARVSQELKGAKVHLGDLKSLSEAPG 100
QY 61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKVMVNRTHLWDCSKIIHOR 120
DB 101 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKVMVNRTHLWDCSKIIHOR 160
QY 121 TMTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLTETVYKFPHPISIQSTFDVIGHYISGERPK 180
DB 161 TMTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLTETVYKFPHPISIQSTFDVIGHYISGERPK 220
QY 181 GQIETEMLKVGATLTGVELVLDNNSVRLQPPKQGMQYLLSQDPSLLQRESSVRLW 240
DB 221 GQIETEMLKVGATLTGVELVLDNNSVRLQPPKQGMQYLLSQDPSLLQRESSVRLW 280
QY 241 KVALVFGFATCATLFFILRKQYLRQERLRKQMOEFPQHEAQLLSRAKPEDRESLSK 300
DB 281 KVALVFGFATCATLFFILRKQYLRQERLRKQMOEFPQHEAQLLSRAKPEDRESLSK 340
QY 301 ACVCLSSPKSCVFLECGHVCSTCYRALPPEPKKPCICROAITRVIPLYS 352
DB 341 ACVCLSSPKSCVFLECGHVCSTCYRALPPEPKKPCICROAITRVIPLYS 392

RESULT 10
ID ABP61460 standard; protein; 352 AA.
XX
AC ABP61460;
DT 30-SEP-2002 (first entry)
XX
DE Human NF-kB activating protein SEQ ID NO 73.
XX
KW Human; NF-kB; nuclear factor kappa B; mouse; antiinflammatory;
KW immunomodulator; cytostatic; antiinfective; osteopathic; nootropic;
KW neuroprotective; anti-HIV; autoimmune disease; cancer; infection;
KW bone disease; AIDS; neurodegenerative disease; ischaemic disorder.
XX
OS Homo sapiens.
XX
PN WO200253737-A1.
XX
PD 11-JUL-2002.
XX
PF 25-DEC-2001; 2001WO-JP011389.
XX
PR 28-DEC-2000; 2000JP-00402288.
XX
PR 26-MAR-2001; 2001JP-00089912.
XX
PR 24-AUG-2001; 2001JP-00254018.
XX
XX (ASAH) ASahi Kasei Kogyo KK.
XX

PI Matsuda A, Honda G, Muramatsu S, Nagano Y;
XX WPI; 2002-583617/62.
DR N-P8DB; ABQ91948.
XX NF-approximatelykB activating gene and expressed protein, applicable in
PT diagnosis and screening inhibitors or promoters to control excessive
PT activation or inhibition for treating e.g. inflammations, autoimmune
PT diseases and cancer.
XX
PS Claim 1; Page 342-344; 841pp; Japanese.
XX
CC The invention relates to a purified protein (I), comprising one of 90
CC fully defined sequences (ABP61424-ABP61513) or a protein based on any of
CC the sequences but with some amino acids deleted, substituted or added and
CC with a NF-kB (nuclear factor kappa B) activating effect. The protein and
CC encoding gene (ABQ91912-ABQ92001) are useful in diagnosis and screening
CC inhibitors or promoters to control excessive activation or inhibition and
CC for treating e.g. inflammations, autoimmune diseases, cancers,
CC infections, bone diseases, AIDS, neurodegenerative diseases or ischaemic
CC disorders
XX
SQ Sequence 352 AA;
Query Match 99.6%; Score 1824; DB 5; Length 352;
Best Local Similarity 99.7%; Pred. No. 5.6e-168;
Matches 351; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MESGGRPSCQFILLGTTTSVTAALYSVYRQKARVSQELKGAKVHLGDLKSLSEAPG 60
DB 1 MESGGRPSCQFILLGTTTSVTAALYSVYRQKARVSQELKGAKVHLGDLKSLSEAPG 60
QY 61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKVMVNRTHLWDCSKIIHOR 120
DB 61 KCPYAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKVMVNRTHLWDCSKIIHOR 120
QY 121 TMTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLTETVYKFPHPISIQSTFDVIGHYISGERPK 180
DB 121 TMTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLTETVYKFPHPISIQSTFDVIGHYISGERPK 180
QY 181 GQIETEMLKVGATLTGVELVLDNNSVRLQPPKQGMQYLLSQDPSLLQRESSVRLW 240
DB 181 GQIETEMLKVGATLTGVELVLDNNSVRLQPPKQGMQYLLSQDPSLLQRESSVRLW 240
QY 241 KVALVFGFATCATLFFILRKQYLRQERLRKQMOEFPQHEAQLLSRAKPEDRESLSK 300
DB 241 KVALVFGFATCATLFFILRKQYLRQERLRKQMOEFPQHEAQLLSRAKPEDRESLSK 300
QY 301 ACVCLSSPKSCVFLECGHVCSTCYRALPPEPKKPCICROAITRVIPLYS 352
DB 301 ACVCLSSPKSCVFLECGHVCSTCYRALPPEPKKPCICROAITRVIPLYS 352
RESULT 11
AAB94353
ID AAB94353 standard; protein; 352 AA.
XX
AC AAB94353;
XX
DT 26-JUN-2001 (first entry)
XX
DE Human protein sequence SEQ ID NO:14873.
XX
KW Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS Homo sapiens.
XX
PN EP1074617-A2.
XX
PD 07-FEB-2001.
XX
PF 28-JUL-2000; 2000EP-00116126.
XX


```
PR 29-JUL-1999; 99JP-00248036.
PR 27-AUG-1999; 99JP-00300253.
PR 11-JAN-2000; 2000JP-00118776.
PR 02-MAY-2000; 2000JP-00183767.
PR 09-JUN-2000; 2000JP-00241899.
XX
XX (HELI-) HELIX RES INST.
XX
XX Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX
XX WPI; 2001-318749/34.
XX
XX Primer sets for synthesizing polynucleotides, particularly the 5602 full-
PT length cDNAs defined in the specification, and for the detection and/or
PT diagnosis of the abnormality of the proteins encoded by the full-length
PT cDNAs.
XX
XX Claim 8; SEQ ID NO 14873; 2537pp + Sequence Listing; English.
XX
XX The present invention describes primer sets for synthesizing 5602 full-
CC length cDNAs defined in the specification. Where a primer set comprises:
CC (a) an oligo-dr primer and an oligonucleotide complementary to the
CC complementary strand of a polynucleotide which comprises one of the 5602
CC nucleotide sequences defined in the specification, where the
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC of an oligonucleotide comprising a sequence complementary to the
CC complementary strand of a polynucleotide which comprises a 5'-end
CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in the
CC specification. The primer sets can be used in antisense therapy and in
CC gene therapy. The primers are useful for synthesizing polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAH92446 to AAH95893
CC represent human amino acid sequences; and AAH13629 to AAH13632 represent
CC oligonucleotides, all of which are used in the exemplification of the
CC present invention
XX
XX Sequence 352 AA;
XX
XX Query Match 99.3%; Score 1818; DB 4; Length 352;
XX Best Local Similarity 99.7%; Pred. No. 2.1e-167;
XX Matches 351; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1 MESGGRPSLCQFILLGTTSSVVTAAALYSYVYQKARVSOELKGAKKVLGDELKSLSEAPG 60
Db 1 MESGGRPSLCQFILLGTTSSVVTAAALYSYVYQKARVSOELKGAKKVLGDELKSLSEAPG 60
QY 61 KCVPAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKMWNTTTLWNCDSKLIHQ 120
Db 61 KCVPAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKMWNTTTLWNCDSKLIHQ 120
QY 121 TINTVPDLVPHEDGDVAVRLKPLDSVDLGLTETVYKFPSPISQFTDVIHYISGERPK 180
Db 121 TINTVPDLVPHEDGDVAVRLKPLDSVDLGLTETVYKFPSPISQFTDVIHYISGERPK 180
QY 181 GIQETEMLKVCATLTGVELVLDNNSVRLQPPKQGMQYLLSSQDFSLQROESSVRLW 240
Db 181 GIQETEMLKVCATLTGVELVLDNNSVRLQPPKQGMQYLLSSQDFSLQROESSVRLC 240
QY 241 KYLALVFGFATCATLFFILRKQYLOQRERLQKQWERFOEHAQLLSRAKPEDRESLKS 300
Db 241 KYLALVFGFATCATLFFILRKQYLOQRERLQKQWERFOEHAQLLSRAKPEDRESLKS 300
QY 301 ACWCILSSPKSCVFLCECHVCSCTECYRALPFPKPCICRQAITRVIPLNS 352
Db 301 ACVCILSSPKSCVFLCECHVCSCTECYRALPFPKPCICRQAITRVIPLNS 352
```

```
RESULT 12
ABU38698
ID ABU38698 standard; protein; 263 AA.
XX
XX AC ABU38698;
XX
XX DT 04-AUG-2003 (first entry)
XX
XX DE Human nucleic acid-associated protein (NAAP) #28.
XX
XX KW Human; gene therapy; nucleic acid-associated protein; NAAP;
KW cell proliferative disorder; cancer; neurological disorder; epilepsy;
KW immune disorder; inflammatory disorder; AIDS; allergy;
KW developmental disorder; Cushing's syndrome.
XX
XX OS Homo sapiens.
XX
XX PN WO2003010329-A2.
XX
XX PD 06-FEB-2003.
XX
XX PF 25-JUL-2002; 2002WO-US023756.
XX
XX PR 26-JUL-2001; 2001US-0308189P.
XX PR 27-JUL-2001; 2001US-0308171P.
XX PR 02-AUG-2001; 2001US-0310139P.
XX PR 03-AUG-2001; 2001US-0309974P.
XX PR 08-AUG-2001; 2001US-0311072P.
XX PR 10-AUG-2001; 2001US-0311642P.
XX PR 10-AUG-2001; 2001US-0311717P.
XX PR 12-OCT-2001; 2001US-0329688P.
XX
XX (INCY-) INCYTE GENOMICS INC.
XX
XX Tang YT, Nguyen DB, Yao MG, Warren BA, Griffin JA, Ison CH;
XX Forsythe IJ, Becha SD, Yue H, Emerling BM, Wallia NK, Richardson TW;
XX Lee EA, Ramkumar J, Elliott VS, He A, Li JX, Hafalia AJA, Yang J;
XX Sanjanwala MM, Xu Y, Arvizu CS, Gandhi AR, Borowsky ML, Tran UK;
XX Burford N, Sprague WW, Baughn MR, Swarnakar A, Policky JL, Lee SY;
XX Jiang X, Jackson A, Chang H;
XX
XX WPI; 2003-248084/24.
XX DR N-PSDB; ABT42547.
XX
XX PT New human nucleic acid associated proteins (NAAP), useful for diagnosing,
XX treating and preventing diseases or conditions associated with the
XX aberrant NAAP expression e.g. cancer, AIDS, atherosclerosis, epilepsy, or
XX infections.
XX
XX PS Claim 1; Page 229; 263pp; English.
XX
XX The invention comprises the amino acid and coding sequences of human
XX nucleic acid-associated proteins (NAAP). The DNA and protein sequences of
XX the invention are useful for diagnosing, treating and preventing diseases
XX or conditions associated with the decreased expression or overexpression
XX of NAAP, such as: cell proliferative disorders (e.g. cancer);
XX neurological disorders (e.g. epilepsy); immune/inflammatory disorders
XX (e.g. AIDS and allergies); and developmental disorders (e.g. Cushing's
XX syndrome). The present amino acid sequence represents a human nucleic
XX acid-associated protein of the invention
XX
XX SQ Sequence 263 AA;
XX
XX Query Match 72.6%; Score 1328.5; DB 6; Length 263;
XX Best Local Similarity 74.7%; Pred. No. 4.5e-120;
XX Matches 263; Conservative 0; Mismatches 0; Indels 89; Gaps 1;
XX
QY 1 MESGGRPSLCQFILLGTTSSVVTAAALYSYVYQKARVSOELKGAKKVLGDELKSLSEAPG 60
Db 1 MESGGRPSLCQFILLGTTSSVVTAAALYSYVYQKARVSOELKGAKKVLGDELKSLSEAPG 60
QY 61 KCVPAVIEGAVRSVKETLNSQFVENCCKGVIQRLTLQEHKMWNTTTLWNCDSKLIHQ 120
```

Db	17					PR	14-AUG-2000;	2000US-0225270P.
						PR	14-AUG-2000;	2000US-0225447P.
						PR	14-AUG-2000;	2000US-0225757P.
Qy	121	TNTVPDLPHEDGVDVAVRLKPLDSVDLGLTVEYKEPHPSIQSTDVIGHYISGERPK	180			PR	14-AUG-2000;	2000US-0225758P.
Db	32	TNTVPDLPHEDGVDVAVRLKPLDSVDLGLTVEYKEPHPSIQSTDVIGHYISGERPK	91			PR	18-AUG-2000;	2000US-0226279P.
						PR	22-AUG-2000;	2000US-0226681P.
Qy	181	GQETEMLKVGATLTGVGELVDNNSVRLQPPKQGMQYVLSQDFSLLRQESSVRLW	240			PR	22-AUG-2000;	2000US-0226868P.
Db	92	GQETEMLKVGATLTGVGELVDNNSVRLQPPKQGMQYVLSQDFSLLRQESSVRLW	151			PR	22-AUG-2000;	2000US-0227182P.
						PR	30-AUG-2000;	2000US-0227009P.
Qy	241	KVALVFGFATCATLFFILRKQYLRQERLRKQMOEFQEHEAQLLSRAKPEDRESLKS	300			PR	01-SEP-2000;	2000US-0229287P.
Db	152	KVALVFGFATCATLFFILRKQYLRQERLRKQMOEFQEHEAQLLSRAKPEDRESLKS	211			PR	01-SEP-2000;	2000US-0229343P.
						PR	01-SEP-2000;	2000US-0229344P.
Qy	301	ACVCLSSFKSCVFLECGHVCSTECYRALPEPKKPCICRQAITRVIPLYS	352			PR	05-SEP-2000;	2000US-0229509P.
Db	212	ACVCLSSFKSCVFLECGHVCSTECYRALPEPKKPCICRQAITRVIPLYS	263			PR	05-SEP-2000;	2000US-0229513P.
						PR	06-SEP-2000;	2000US-0230437P.
						PR	06-SEP-2000;	2000US-0230438P.
						PR	08-SEP-2000;	2000US-0231242P.
						PR	08-SEP-2000;	2000US-0231243P.
						PR	08-SEP-2000;	2000US-0231244P.
						PR	08-SEP-2000;	2000US-0231413P.
						PR	08-SEP-2000;	2000US-0231414P.
						PR	08-SEP-2000;	2000US-0232080P.
						PR	08-SEP-2000;	2000US-0232081P.
						PR	12-SEP-2000;	2000US-0231968P.
						PR	14-SEP-2000;	2000US-0232397P.
						PR	14-SEP-2000;	2000US-0232398P.
						PR	14-SEP-2000;	2000US-0232399P.
						PR	14-SEP-2000;	2000US-0232400P.
						PR	14-SEP-2000;	2000US-0232401P.
						PR	14-SEP-2000;	2000US-0233063P.
						PR	14-SEP-2000;	2000US-0233064P.
						PR	14-SEP-2000;	2000US-0233065P.
						PR	21-SEP-2000;	2000US-0234223P.
						PR	21-SEP-2000;	2000US-0234274P.
						PR	25-SEP-2000;	2000US-0234997P.
						PR	25-SEP-2000;	2000US-0234998P.
						PR	26-SEP-2000;	2000US-0235484P.
						PR	27-SEP-2000;	2000US-0235834P.
						PR	27-SEP-2000;	2000US-0235836P.
						PR	29-SEP-2000;	2000US-0236327P.
						PR	29-SEP-2000;	2000US-0236327P.
						PR	29-SEP-2000;	2000US-0236367P.
						PR	29-SEP-2000;	2000US-0236368P.
						PR	29-SEP-2000;	2000US-0236369P.
						PR	29-SEP-2000;	2000US-0236370P.
						PR	02-OCT-2000;	2000US-0236802P.
						PR	02-OCT-2000;	2000US-0237037P.
						PR	02-OCT-2000;	2000US-0237038P.
						PR	02-OCT-2000;	2000US-0237039P.
						PR	02-OCT-2000;	2000US-0237040P.
						PR	13-OCT-2000;	2000US-0239935P.
						PR	13-OCT-2000;	2000US-0239937P.
						PR	20-OCT-2000;	2000US-0240960P.
						PR	20-OCT-2000;	2000US-0241221P.
						PR	20-OCT-2000;	2000US-0241785P.
						PR	20-OCT-2000;	2000US-0241786P.
						PR	20-OCT-2000;	2000US-0241787P.
						PR	20-OCT-2000;	2000US-0241808P.
						PR	20-OCT-2000;	2000US-0241809P.
						PR	20-OCT-2000;	2000US-0241826P.
						PR	01-NOV-2000;	2000US-0244617P.
						PR	08-NOV-2000;	2000US-0246474P.
						PR	08-NOV-2000;	2000US-0246475P.
						PR	08-NOV-2000;	2000US-0246476P.
						PR	08-NOV-2000;	2000US-0246477P.
						PR	08-NOV-2000;	2000US-0246478P.
						PR	08-NOV-2000;	2000US-0246523P.
						PR	08-NOV-2000;	2000US-0246524P.
						PR	08-NOV-2000;	2000US-0246525P.
						PR	08-NOV-2000;	2000US-0246526P.
						PR	08-NOV-2000;	2000US-0246527P.

PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-02559678P.
PR (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI: 2001-488783/53.
XX N-PSDB; AAS26296.
PT New nucleic acid molecules encoding 461 human secreted proteins for
PT diagnosing, preventing, treating or ameliorating medical conditions and
PT used as food additives or preservatives.
PS
PS Claim 11; SEQ ID NO 1262; 980pp; English.
XX
CC The invention relates to isolated nucleic acid molecules and their
CC encoded secreted proteins. The nucleic acids and proteins are used to
CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
CC in diagnosing a pathological condition or susceptibility to a
CC pathological condition. Antibodies to the proteins can also be used in
CC alleviating symptoms associated with the disorders and in diagnostic
CC immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays
CC (ELISA). Disorders which are diagnosed or treated include autoimmune
CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
CC arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,
CC nervous system disorders e.g. Alzheimer's disease, infections caused by
CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection,
CC and many other disorders listed in the specification. The polypeptides
CC can also be used to aid wound healing and epithelial cell proliferation,
CC to prevent skin aging due to sunburn, to maintain organs before
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,

CC minerals, cofactors and other nutritional components. The present
CC sequence represents a novel secreted protein of the invention. Note: The
CC sequence data for this patent did not form part of the printed

Query Match 49.2%; Score 901; DB 4; Length 174;
Best Local Similarity 99.4%; Pred. No. 7 5e-79;
Matches 173; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 179 PKGIQTEEMLVKVGATLTGVLVLDNNSVRLQPPKQGMQYVLSQDFDLSLLQROESSVR 238
|||
Db 1 PKGIQTEEMLVKVGATLTGVLVLDNNSVRLQPPKQGMQYVLSQDFDLSLLQROESSVR 60
|||

QY 239 LMKVLALVFGFATCATLFFILRKQYLQROERLRLKMQOEFOEHEAQLLSRAKPEDRESL 238
|||
Db 61 LMKVLALVFGFATCATLFFILRKQYLQROERLRLKMQOEFOEHEAQLLSRAKPEDRESL 120
|||

QY 299 KSACVVCLSSFKSCVFLGCGHVCSTCYRALPEPKKPCICQAITRVIPLYS 352
|||
Db 121 KSACVVCLSSFKSCVFLGCGHVCSTCYRALPEPKKPCICQAITRVIPLYS 174
|||

RESULT 14
ABUS5378
ID ABUS5378 standard; protein; 174 AA.
XX
AC ABUS5378;
XX
DT 18-MAR-2003 (first entry)
XX
DE Human novel polypeptide #465.
XX
KW Human; neural disorder; immune system disorder; renal disorder;
KW muscular disorder; respiratory disease; reproductive disorder;
KW gastrointestinal disorder; pulmonary disorder; cardiovascular disorder;
KW hyperproliferative disorder; inflammatory disease; allergic reaction;
KW blood related disorder; cancer; immunosuppressive; antiinflammatory;
KW cardiovascular; nephrotropic; cytostatic; antiallergic; thrombolytic;
KW haemostatic; antiarteriosclerotic.
XX
OS Homo sapiens.
XX
PN US2002132753-A1.
XX
PD 19-SEP-2002.
XX
PF 17-JAN-2001; 2001US-00764864.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 28-JUN-2000; 2000US-0214888P.
PR 07-JUL-2000; 2000US-0218647P.
PR 07-JUL-2000; 2000US-0218680P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 22-AUG-2000; 2000US-0226868P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 05-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.

PR 08-SEP-2000; 2000US-0231413P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 27-SEP-2000; 2000US-0235834P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239393P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241809P.
PR 01-NOV-2000; 2000US-0244617P.
PR 17-NOV-2000; 2000US-0249299P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
XX
PA (ROSE/) ROSEN C A.
PA (RUBE/) RUBEN S M.
PA (BARA/) BARASH S C.
XX
XX Rosen CA, Ruben SM, Barash SC;
XX
XX WPI; 2003-147444/14.
DR N-PSDB; ABX73637.
XX
PT New polypeptides and nucleic acids, useful in gene therapy for treating,
PT inhibiting or preventing e.g. neural, immune system, muscular,
PT respiratory, reproductive, gastrointestinal, pulmonary, cardiovascular or
PT renal disorders.
XX
PS Claim 11; SEQ ID NO 1262; 402pp; English.
XX
XX The invention relates to human novel polypeptides and their associated
XX polynucleotides. The polypeptides and polynucleotides are useful in gene
XX therapy for treating, inhibiting or preventing neural disorders, immune
XX system disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis
XX and multiple sclerosis), muscular disorders, respiratory diseases (e.g.
XX nasal vestibulitis, nasal polyps and sinusitis), reproductive disorders,
XX gastrointestinal disorders, pulmonary disorders, cardiovascular disorders
XX (e.g. congenital heart defects, Ebstein's anomaly and hypoplastic left
XX heart syndrome), renal disorders (e.g. acute kidney failure and end-stage
XX renal disease), hyperproliferative disorders (e.g. Hodgkin's disease and
XX leukemia), inflammatory diseases (e.g. septic shock, bursitis and
XX appendicitis), allergic reactions and conditions (e.g. asthma), blood
XX related disorders (e.g. thrombosis, atherosclerosis and myocardial
XX infarction) and cancerous diseases. Sequences ABU54914-ABU55699 and
XX ABU55748 represent human novel polypeptides of the invention
XX
SQ Sequence 174 AA;
Query Match 49.2%; Score 901; DB 6; Length 174;
Best Local Similarity 99.4%; Pred. No. 7.5e-79;
Matches 173; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 179 PKGIQTEEMLVKVGATLTGVGELVLDNNSVRLQPPKQGMQYVLLSSQDFDLSLLQQRQSSVR 238
DB 1 PKGIQTEEMLVKVGATLTGVGELVLDNNSVRLQPPKQGMQYVLLSSQDFDLSLLQQRQSSVR 60
QY 239 LKWLALVFGFATCATLFFILRKQYLQRLKQMOEFQHEAQLLSRAKPEDRESL 298
DB 61 LKWLALVFGFATCATLFFILRKQYLQRLKQMOEFQHEAQLLSRAKPEDRESL 120
QY 299 KSACVVCLSSPKSCVFLECGHVCSTCYRALPEPKKPCICRQAITRVIFLYNS 352
|||||

DB 121 KSACVVCLSSPKSCVFLECGHVCSTCYRALPEPKKPCICRQAITRVIFLYNS 174
RESULT 15
ABB90304
ID ABB90304 standard; protein; 165 AA.
XX
XX ABB90304;
XX
XX 24-MAY-2002 (first entry)
XX
XX Human polypeptide SEQ ID NO 2680.
XX
XX Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
XX antitallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
XX vulvar; anticonvulsant; antibacterial; antifungal; antiparasitic;
XX cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
XX neurological disease; infection; human; secreted protein.
XX
XX Homo sapiens.
XX
XX WO200190304-A2.
XX
XX 29-NOV-2001.
XX
XX 18-MAY-2001; 2001WO-US016450.
XX
XX 19-MAY-2000; 2000US-0205515P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Birse CE, Rosen CA;
XX
XX WPI; 2002-122018/16.
DR N-PSDB; ABL90713.
XX
PT Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
PT prevention of neural, immune system, muscular, reproductive,
PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative
PT disorders.
XX
XX Claim 11; SEQ ID NO 2680; 2081pp + Sequence Listing; English.
XX
XX The invention relates to novel genes (ABL89449-ABL90853) and proteins
XX (ABB9040-ABB9044) useful for preventing, treating or ameliorating
XX medical conditions e.g. by protein or gene therapy. The genes are
XX isolated from a range of human tissues disclosed in the specification.
XX The nucleic acids, proteins, antibodies and (ant)agonists are useful in
XX the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
XX ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
XX breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
XX disorders e.g. Addison's disease, allergies, autoimmune haemolytic
XX anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
XX multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
XX cardiovascular disorders such as myocardial ischaemia; (d) wound healing
XX ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
XX infectious diseases such as viral, bacterial, fungal and parasitic
XX infections. Note: the sequence data for this patent did not form part of
XX the printed specification, but was obtained in electronic format directly
XX from WIPO at ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 165 AA;
Query Match 46.6%; Score 854; DB 5; Length 165;
Best Local Similarity 99.4%; Pred. No. 2.5e-74;
Matches 164; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 188 MLKVGATLTGVGELVLDNNSVRLQPPKQGMQYVLLSSQDFDLSLLQQRQSSVRLMKVLALVF 247
DB 1 MLKVGATLTGVGELVLDNNSVRLQPPKQGMQYVLLSSQDFDLSLLQQRQSSVRLMKVLALVF 60
QY 248 GFATCATLFFILRKQYLQRLKQMOEFQHEAQLLSRAKPEDRESLKCACVVCLS 307
|||||

Db 61 GFATCATLFFILRKQVLRQERLRLKOMQBEFQEHQAQLLSRAKPEDXESLKSACVVCLS 120
QY 308 SFKSCVFLECGHVCSTECYRALPEPKKCPICQAITRVIPLYS 352
Db 121 SFKSCVFLECGHVCSTECYRALPEPKKCPICQAITRVIPLYS 165

Search completed: November 6, 2004, 17:38:18
Job time : 160 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 6, 2004, 17:33:13 ; Search time 40 Seconds
(without alignments)
583.598 Million cell updates/sec

Title: US-09-978-360A-437

Perfect score: 1831

Sequence: 1 MESGGRSLCQFILLGTTTSV.....PKKPCICRQAIATRVIPLYNS 352

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 478139 seqs, 66318000 residues

Total number of hits satisfying chosen parameters: 478139

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents AA:*

- 1: /cgn2_6/prodata/1/1aa/5A_COMB.pep:*
- 2: /cgn2_6/prodata/1/1aa/5B_COMB.pep:*
- 3: /cgn2_6/prodata/1/1aa/6A_COMB.pep:*
- 4: /cgn2_6/prodata/1/1aa/6B_COMB.pep:*
- 5: /cgn2_6/prodata/1/1aa/PCTUS_COMB.pep:*
- 6: /cgn2_6/prodata/1/1aa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1831	100.0	352	4	US-09-599-360B-105
2	445	24.3	91	3	US-08-905-223-421
3	163	8.9	372	3	US-09-324-455-2
4	155.5	8.5	723	4	US-09-434-408-2
5	151	8.2	350	4	US-09-270-767-58582
6	151	8.2	559	4	US-09-270-767-43239
7	144.5	7.9	438	5	PCT-US95-05922A-2
8	144.5	7.9	618	3	US-08-569-749-2
9	144.5	7.9	618	3	US-09-069-023-29
10	144.5	7.9	618	5	PCT-US96-12860-2
11	138.5	7.6	618	2	US-09-212-971-8
12	138.5	7.6	618	3	US-08-511-485-8
13	138.5	7.6	618	3	US-08-800-929A-8
14	138.5	7.6	618	3	US-09-617-053A-8
15	138.5	7.6	618	4	US-09-201-936-8
16	138.5	7.6	618	4	US-09-011-356-8
17	138.5	7.6	618	4	US-09-672-717-223
18	138.5	7.6	618	4	US-09-201-932-8
19	137.5	7.5	604	2	US-08-511-485-6
20	137.5	7.5	604	3	US-09-212-971-6
21	137.5	7.5	604	3	US-08-800-929A-6
22	137.5	7.5	604	3	US-09-617-053A-6
23	137.5	7.5	604	4	US-09-201-936-6
24	137.5	7.5	604	4	US-09-011-356-6
25	137.5	7.5	604	4	US-09-672-717-221
26	137.5	7.5	604	4	US-09-201-932-6
27	136.5	7.5	602	4	US-09-201-936-40

ALIGNMENTS

RESULT 1

US-09-599-360B-105
; Sequence 105, Application US/09599360B
; Patent No. 6548633

; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, J.B.

; APPLICANT: Bouguetieret, L.

; TITLE OF INVENTION: Complementary DNA's Encoding Proteins with Signal Peptides

; FILE REFERENCE: GENSET.050CP3

; CURRENT APPLICATION NUMBER: US/09/599,360B

; CURRENT FILING DATE: 2000-06-21

; PRIOR APPLICATION NUMBER: 60/113,686

; PRIOR FILING DATE: 1998-12-22

; PRIOR APPLICATION NUMBER: 60/141,032

; PRIOR FILING DATE: 1999-06-25

; PRIOR APPLICATION NUMBER: 09/469,099

; PRIOR FILING DATE: 1999-12-21

; NUMBER OF SEQ ID NOS: 123

; SOFTWARE: Patent.pm

; SEQ ID NO 105

; LENGTH: 352

; TYPE: PRT

; ORGANISM: Homo Sapiens

; FEATURE:

; NAME/KEY: SIGNAL

; LOCATION: -23..-1

US-09-599-360B-105

Query Match 100.0%; Score 1831; DB 4; Length 352;
Best Local Similarity 100.0%; Pred. No. 2e-192;
Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	MESGGRSLCQFILLGTTTSVTAALYSVYRKARVSQELKCAKVKHGLGDKSLSEAPG	60
Db	1	MESGGRSLCQFILLGTTTSVTAALYSVYRKARVSQELKCAKVKHGLGDKSLSEAPG	60
QY	61	KCPYAVIEGAVRSVKETLSNQFVENCCKGVIQRLTLOEHKMWNRTHLWNCDSKIIHQ	120
Db	61	KCPYAVIEGAVRSVKETLSNQFVENCCKGVIQRLTLOEHKMWNRTHLWNCDSKIIHQ	120
QY	121	TNTVPFDLVPHEDGVAVVAVLPKDSVDLGLETVEYKFKHPISQSFDTVIGHYISGERPK	180
Db	121	TNTVPFDLVPHEDGVAVVAVLPKDSVDLGLETVEYKFKHPISQSFDTVIGHYISGERPK	180
QY	181	GIQTEMLKVGATLTGVLGELDNNNSVRLQPKQGMQYVLLSSODFSLLRQESSVRLW	240
Db	181	GIQTEMLKVGATLTGVLGELDNNNSVRLQPKQGMQYVLLSSODFSLLRQESSVRLW	240
QY	241	KVLALVFGFATCATLFFILRKQYLQRLKQMQBEFQHEAQLLSRAKPEDRESLKS	300

Db 241 KVALVFGFATCATLFFILRKOYLQORQLRLKQMQEFPQHEAQLLRAPKPEDRESLS 300
QY 301 ACVVCLSFKSCVFLECGHVCSTCYRALPEPKKPCICRQAITRVIPLYNS 352
Db 301 ACVVCLSFKSCVFLECGHVCSTCYRALPEPKKPCICRQAITRVIPLYNS 352
RESULT 2
US-08-905-223-421
; Sequence 421, Application US/08905223
; Patent No. 6222029
; GENERAL INFORMATION:
; APPLICANT: Edwards, Jean-Baptiste D.
; APPLICANT: Duclert, Aymeric
; APPLICANT: Lacroix, Bruno
; TITLE OF INVENTION: 5' ESTS FOR SECRETED PROTEINS
; NUMBER OF SEQUENCES: 503
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 501 West Broadway
; CITY: San Diego
; STATE: California
; COUNTRY: USA
; ZIP: 92101-3505
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy Disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Win95
; SOFTWARE: Word
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/905,223
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Israelsen, Ned A.
; REGISTRATION NUMBER: 29,655
; REFERENCE/DOCKET NUMBER:
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 235-8550
; TELEFAX: (619) 235-0176
; INFORMATION FOR SEQ ID NO: 421:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 91 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: LINEAR
; MOLECULE TYPE: PROTEIN
; ORIGINAL SOURCE:
; ORGANISM: Homo Sapiens
; TISSUE TYPE: Brain
; FEATURE:
; NAME/KEY: sig_peptide
; LOCATION: -23...-1
; IDENTIFICATION METHOD: Von Heijne matrix
; OTHER INFORMATION: score 4.4
; OTHER INFORMATION: seq QFILLGTTSVVTA/AL
US-08-905-223-421
Query Match 24.3%; Score 445; DB 3; Length 91;
Best Local Similarity 98.9%; Pred. No. 5.2e-41;
Matches 89; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MESGGRSLCQFILLGTTSVVTAALSYVYRQKARVSQELKGAKKHVHGEDLKSILSEAPG 60
Db 1 MESGGRSLCQFILLGTTSVVTAALSYVYRQKARVSQELKGAKKHVHGEDLKSILSEAPG 60
QY 61 KCVYAVIEGAVRSVKETLNSQFVENCXGV 90
Db 61 KCVYAVIEGAVRSVKETLNSQFVENCXGV 90
RESULT 3
US-09-324-455-2

; Sequence 2, Application US/09324455
; Patent No. 6326481
; GENERAL INFORMATION:
; APPLICANT: Iowe, David
; TITLE OF INVENTION: NOVEL MOLECULES OF THE AIP-RELATED
; TITLE OF INVENTION: PROTEIN FAMILY AND USES THEREOF
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/324,455
; FILING DATE: 02-JUN-1999
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/087,761
; FILING DATE: 02-JUN-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/069001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 372 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-324-455-2
Query Match 8.9%; Score 163; DB 3; Length 372;
Best Local Similarity 30.1%; Pred. No. 5.2e-09;
Matches 40; Conservative 29; Mismatches 48; Indels 16; Gaps 5;
QY 222 SSQDFSLILQRQESSYR-LMKVLALYF-GFATCATLFFILRKOYLQORQLRLKQMQEFP 279
Db 254 SLSDLSLDDVEGMSVRQLKEILARNFVNYSCCERWELVEK-----VNRLYKEN 303
QY 280 QEHEAQLLRAPKPEDRESLSKACVCLSSFKSCVFLECGHVCSTCYRALPEPKKPCIC 339
Db 304 EENQKSYGERLQLODEED-DSLCRICMDAVIDCVLLECGHVMVCTCKGRMSE---CPIC 359
QY 340 RQAITRVIPLYNS 352
Db 360 RQYVWRVAVHVKFS 372
RESULT 4
US-09-434-408-2
; Sequence 2, Application US/09434408
; Patent No. 6440697
; GENERAL INFORMATION:
; APPLICANT: Venezia, Domenick
; APPLICANT: Grossmann, Angelika
; TITLE OF INVENTION: RING FINGER PROTEIN ZAPOF3
; FILE REFERENCE: 98-41
; CURRENT APPLICATION NUMBER: US/09/434,408
; CURRENT FILING DATE: 1999-11-04
; EARLIER APPLICATION NUMBER: US 60/108,258
; EARLIER FILING DATE: 1998-11-12
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: FastSeq for Windows Version 3.0


```

Best Local Similarity   31.5%; Pred. No. 2.1e-07;
Matches    34; Conservative    18; Mismatches    34; Indels    22; Gaps    3;

QY      264 LQRERLRLLKMQEFOEH-----EAQLLSRAK-----PEDRESLKSA CVV 304
Db      311 LKDLEGTVVQLKEVLMLHRVDYKGCCCKOELLDRVSRMLMKTMRCEFAVKLATDELCKI 370
QY      305 CLSFKSCVFLECHGVCSCTECVRALPEPKKCPICRQAIRVIFLYNS 352
Db      371 CMDAPIECVFLECHGMATCISCGKVLNE---CPICROYIVRVVFFRA 415

RESULT 7
PCT-US95-05922A-2
; Sequence 2, Application PC/TUS9505922A
; GENERAL INFORMATION:
; APPLICANT: HE, ET AL.
; TITLE OF INVENTION: Human Inhibitor of Apoptosis Gene 1
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CARELLA, BYRNE, BAIN, GILFILLAN,
; ADDRESSEE: CECCHI, STEWART & OLSTEIN
; STREET: 6 BECKER FARM ROAD
; CITY: ROSELAND
; STATE: NEW JERSEY
; COUNTRY: USA
; ZIP: 07068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 INCH DISKETTE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WORD PERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/05922A
; FILING DATE: 11 MAY 1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: FERRARO, GREGORY D.
; REGISTRATION NUMBER: 36,134
; REFERENCE/DOCKET NUMBER: 325800-292
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201-994-1700
; TELEFAX: 201-994-1744
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 438 AMINO ACIDS
; TYPE: AMINO ACID
; STRANDEDNESS:
; TOPOLOGY: LINEAR
; MOLECULE TYPE: PROTEIN
; PCT-US95-05922A-2

Query Match          7.9%; Score 144.5; DB 5; Length 438;
Best Local Similarity 21.9%; Pred. No. 7.4e-07;
Matches     68; Conservative    50; Mismatches   118; Indels    75; Gaps    13;

QY      82 QFVENCKGVIQRLTLOEHKMWNRTTHLNDCKSIHQRTNTVPFLVPHEGDVAVRV 141
Db      163 EFDVEIQGRYPHLL--EQLLSTSDTTGEENADPPPIH-----FGPGESSEDADVMM 211
QY      142 LKPL--DSVDLGL-----ETVVEKFHPISIQSF---TDVIGHVISGERPKGIQE----TE 186
Db      212 NTFVKSALFMGNFRDLVKQT VQS KILLTGGENKYTVNDIVSALLNADEKRREEKEKQAE 271
QY      187 EMLKVGAATLTGVGEL-----VLDN-----NSVRLOPP---KQGMYVLSSOD-FD 227
Db      272 ENASDDLSLRKRNRMALFOQLTCVLPILDNLKANVINVKQHEDIKQKTQIPLAARELID 331
QY      228 SLLQRQESSVRLWKUALVFGFATCATLFPILRKQYLQREQ-----RLRLKMQEEFQEQ 281

```

Db 332 TILVKGNAANIFKNCLKEIDSTLYKNLFVDMKMKYIPTEDYSGLSLEEQRLRLOE--- 388
QY 282 HEAQLLSRAKPEDRESLSKACVCLSSFKSCVFLGCHVSCCTCYRALPEPKKPCICRQ 341
Db 389 -----RTCKVMDKESVVFIPGCHLWVQEC---APSLRKPCICRG 427
QY 342 AITRVIPLVNS 352
Db 428 IIKGTVRTFLS 438

RESULT 8
US-08-569-749-2
; Sequence 2, Application US/08569749
; Patent No. 6187557
; GENERAL INFORMATION:
; APPLICANT: Rothe, Mike
; APPLICANT: Goeddel, David V
; TITLE OF INVENTION: INHIBITORS OF APOPTOSIS
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FLEHR, HOBBACH, TEST, ALBRITTON & HERBERT
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: US/08/569,749
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Brenner, David J.
; REGISTRATION NUMBER: 24,774
; REFERENCE/DOCKET NUMBER: A-62464/DJB
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415)781-1989
; TELEFAX: (415)398-3249
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 618 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-569-749-2

Query Match 7.9%; Score 144.5; DB 3; Length 618;
Best Local Similarity 21.9%; Pred. No. 1.3e-06;
Matches 68; Conservative 50; Mismatches 118; Indels 75; Gaps 13;

QY 82 QFVENCXGVIQRLTLOEHKVMNRTHLWDCSKIIHQRTNTPFDLPVPHEDGVDVAVRV 141
Db 343 EFVDEIQGRYPHLL--EQLLSTSDTTGEENADPPIH-----FGPGESSEDVMM 391
QY 142 LKPL--DSVDLGL-----ETVVEKHPHSIQSF---TDVIGHVISGERPKGIOE---TE 186
Db 392 NTPVKSALWGFNRDLVKQTVQSKILTTGENTYKTVNDIVSALLNADEKREKEKEQAE 451
QY 187 EMLKVGATLTGVGEL-----VLDN-----NSVRLQPP---KQGMQYVLSQD--FD 227
Db 452 EMASDDLILIRKNRMALFQQLTCVLPILDNLKANVINKQEHDIKQKTIPLQARELID 511
QY 228 SLLQROESSVRLKVLALVFGPATCATLFFILRKQYLQOE-----RLRLKQOEFEQ 281
Db 512 TILVKGNAANIFKNCLKEIDSTLYKNLFVDMKMKYIPTEDYSGLSLEEQRLRLOE--- 568
QY 282 HEAQLLSRAKPEDRESLSKACVCLSSFKSCVFLGCHVSCCTCYRALPEPKKPCICRQ 341
Db 569 -----RTCKVMDKESVVFIPGCHLWVQEC---APSLRKPCICRG 607

Query Match 7.9%; Score 144.5; DB 3; Length 618;
Best Local Similarity 21.9%; Pred. No. 1.3e-06;
Matches 68; Conservative 50; Mismatches 118; Indels 75; Gaps 13;

QY 82 QFVENCXGVIQRLTLOEHKVMNRTHLWDCSKIIHQRTNTPFDLPVPHEDGVDVAVRV 141
Db 343 EFVDEIQGRYPHLL--EQLLSTSDTTGEENADPPIH-----FGPGESSEDVMM 391
QY 142 LKPL--DSVDLGL-----ETVVEKHPHSIQSF---TDVIGHVISGERPKGIOE---TE 186
Db 392 NTPVKSALWGFNRDLVKQTVQSKILTTGENTYKTVNDIVSALLNADEKREKEKEQAE 451
QY 187 EMLKVGATLTGVGEL-----VLDN-----NSVRLQPP---KQGMQYVLSQD--FD 227
Db 452 EMASDDLILIRKNRMALFQQLTCVLPILDNLKANVINKQEHDIKQKTIPLQARELID 511
QY 228 SLLQROESSVRLKVLALVFGPATCATLFFILRKQYLQOE-----RLRLKQOEFEQ 281
Db 512 TILVKGNAANIFKNCLKEIDSTLYKNLFVDMKMKYIPTEDYSGLSLEEQRLRLOE--- 568
QY 282 HEAQLLSRAKPEDRESLSKACVCLSSFKSCVFLGCHVSCCTCYRALPEPKKPCICRQ 341

Db 569 -----RTCKVMDKESVVFIPGCHLWVQEC---APSLRKPCICRG 607
QY 342 AITRVIPLVNS 352
Db 608 IIKGTVRTFLS 618

RESULT 9
US-09-069-023-29
; Sequence 2, Application US/09069023A
; Patent No. 6348573
; GENERAL INFORMATION:
; APPLICANT: Nunez, Gabriel
; APPLICANT: Inohara, Naohiro
; APPLICANT: Koseki, Takeyoshi
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR IDENTIFYING APOPTOSIS
; TITLE OF INVENTION: SIGNALING PATHWAY INHIBITORS AND ACTIVATORS
; FILE REFERENCE: UM-03333
; CURRENT APPLICATION NUMBER: US/09/069,023A
; CURRENT FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 29
; LENGTH: 618
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-069-023-29

Query Match 7.9%; Score 144.5; DB 3; Length 618;
Best Local Similarity 21.9%; Pred. No. 1.3e-06;
Matches 68; Conservative 50; Mismatches 118; Indels 75; Gaps 13;

QY 82 QFVENCXGVIQRLTLOEHKVMNRTHLWDCSKIIHQRTNTPFDLPVPHEDGVDVAVRV 141
Db 343 EFVDEIQGRYPHLL--EQLLSTSDTTGEENADPPIH-----FGPGESSEDVMM 391
QY 142 LKPL--DSVDLGL-----ETVVEKHPHSIQSF---TDVIGHVISGERPKGIOE---TE 186
Db 392 NTPVKSALWGFNRDLVKQTVQSKILTTGENTYKTVNDIVSALLNADEKREKEKEQAE 451
QY 187 EMLKVGATLTGVGEL-----VLDN-----NSVRLQPP---KQGMQYVLSQD--FD 227
Db 452 EMASDDLILIRKNRMALFQQLTCVLPILDNLKANVINKQEHDIKQKTIPLQARELID 511
QY 228 SLLQROESSVRLKVLALVFGPATCATLFFILRKQYLQOE-----RLRLKQOEFEQ 281
Db 512 TILVKGNAANIFKNCLKEIDSTLYKNLFVDMKMKYIPTEDYSGLSLEEQRLRLOE--- 568
QY 282 HEAQLLSRAKPEDRESLSKACVCLSSFKSCVFLGCHVSCCTCYRALPEPKKPCICRQ 341
Db 569 -----RTCKVMDKESVVFIPGCHLWVQEC---APSLRKPCICRG 607

Query Match 7.9%; Score 144.5; DB 3; Length 618;
Best Local Similarity 21.9%; Pred. No. 1.3e-06;
Matches 68; Conservative 50; Mismatches 118; Indels 75; Gaps 13;

QY 82 QFVENCXGVIQRLTLOEHKVMNRTHLWDCSKIIHQRTNTPFDLPVPHEDGVDVAVRV 141
Db 343 EFVDEIQGRYPHLL--EQLLSTSDTTGEENADPPIH-----FGPGESSEDVMM 391
QY 142 LKPL--DSVDLGL-----ETVVEKHPHSIQSF---TDVIGHVISGERPKGIOE---TE 186
Db 392 NTPVKSALWGFNRDLVKQTVQSKILTTGENTYKTVNDIVSALLNADEKREKEKEQAE 451
QY 187 EMLKVGATLTGVGEL-----VLDN-----NSVRLQPP---KQGMQYVLSQD--FD 227
Db 452 EMASDDLILIRKNRMALFQQLTCVLPILDNLKANVINKQEHDIKQKTIPLQARELID 511
QY 228 SLLQROESSVRLKVLALVFGPATCATLFFILRKQYLQOE-----RLRLKQOEFEQ 281
Db 512 TILVKGNAANIFKNCLKEIDSTLYKNLFVDMKMKYIPTEDYSGLSLEEQRLRLOE--- 568
QY 282 HEAQLLSRAKPEDRESLSKACVCLSSFKSCVFLGCHVSCCTCYRALPEPKKPCICRQ 341

RESULT 10
PCT-US96-12860-2
; Sequence 2, Application PC/TUS9612860
; GENERAL INFORMATION:
; APPLICANT: TULARIK, INC.
; TITLE OF INVENTION: INHIBITORS OF APOPTOSIS
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FLEHR, HOBBACH, TEST, ALBRITTON & HERBERT
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:


```
; EARLIER APPLICATION NUMBER: 60/017,354
; EARLIER FILING DATE: 1996-04-26
; EARLIER APPLICATION NUMBER: 60/030,590
; EARLIER FILING DATE: 1996-11-14
; EARLIER APPLICATION NUMBER: 08/800,929
; EARLIER FILING DATE: 1997-02-13
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 618
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-212-971-8

Query Match          7.6%; Score 138.5; DB 3; Length 618;
Best Local Similarity 21.5%; Pred. No. 5.9e-06;
Matches 67; Conservative 50; Mismatches 119; Indels 75; Gaps 13;

QY 82 QFVENCQGVQIQLTLOEHKQVNRTHLWDCSKIIHQRTNTVPFDLVPHEDGVDVAVRV 141
DB 343 EFVDEIQGRYPHLL--EQLLSTSDTTGEENADPPIIH-----FGPGESSEDAVMM 391

QY 142 LKPL--DSVDLGL-----ETVVEKFHPSIQSF---TDVIGHVISGERPKGIOE---TE 186
DB 392 NTPVKSALMGFNRLDVKTLSKILTTGENYKTVNDIVSALLNAEDEKREBEKEKQAE 451

QY 187 EMLKVGATLTGVGEL-----VLDN-----NSVRLQPP---KQGMYYLSSQD--FD 227
DB 452 EMASDDLILIRKRMALFOQLTCLVPLDNLKANVINKEHDIIRKQTIPLQARELID 511

QY 228 SLLQROESSVRLWKVLALVFGFATCATLFLIRKQYLQOE-----RLRLKQMQEFOE 281
DB 512 TIWKGNAANIIFNCLKEIDSTLYKNLFVDKNMKYIPTEDVSGLSLEEQRLQES--- 568

QY 282 HEAQLLSRAKPEDRESLSKACVCLSSFKSCVFLECGHVCSTCEYRALPEPKKPCICRQ 341
DB 569 -----RTCKVMDKESVSVFIPGHLVVCQEC---APSLKPCICRG 607

QY 342 AITRVIPLVNS 352
DB 608 IIRGTVRTFLS 618

RESULT 13
US-08-800-929A-8
; Sequence 8, Application US/08800929A
; Patent No. 6133437
; GENERAL INFORMATION:
; APPLICANT: Korneluk, Robert G
; APPLICANT: MacKenzie, Alexander E
; APPLICANT: Liston, Peter
; APPLICANT: Baird, Stephen
; APPLICANT: Tsang, Benjamin K
; APPLICANT: Pratt, Christine
; TITLE OF INVENTION: DETECTION AND MODULATION OF
; TITLE OF INVENTION: IAPS AND NAIP FOR THE DIAGNOSIS AND TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: DISEASE
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Clark & Elbing LLP
; STREET: 176 Federal Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/800,929A
; FILING DATE: 13-FEB-1997

; CLASSIFICATION: 424
; PRIOR APPLICATION DATA: 60/030,590
; APPLICATION NUMBER: 60/030,590
; FILING DATE: 14-NOV-1996
; APPLICATION NUMBER: 60/017,354
; FILING DATE: 26-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Bieser-Brady, Kristina
; REGISTRATION NUMBER:
; REFERENCE/DOCKET NUMBER: 07891/009001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-428-0200
; TELEFAX: 617-428-7045
; TELEX:
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 618 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-800-929A-8

Query Match          7.6%; Score 138.5; DB 3; Length 618;
Best Local Similarity 21.5%; Pred. No. 5.9e-06;
Matches 67; Conservative 50; Mismatches 119; Indels 75; Gaps 13;

QY 82 QFVENCQGVQIQLTLOEHKQVNRTHLWDCSKIIHQRTNTVPFDLVPHEDGVDVAVRV 141
DB 343 EFVDEIQGRYPHLL--EQLLSTSDTTGEENADPPIIH-----FGPGESSEDAVMM 391

QY 142 LKPL--DSVDLGL-----ETVVEKFHPSIQSF---TDVIGHVISGERPKGIOE---TE 186
DB 392 NTPVKSALMGFNRLDVKTLSKILTTGENYKTVNDIVSALLNAEDEKREBEKEKQAE 451

QY 187 EMLKVGATLTGVGEL-----VLDN-----NSVRLQPP---KQGMYYLSSQD--FD 227
DB 452 EMASDDLILIRKRMALFOQLTCLVPLDNLKANVINKEHDIIRKQTIPLQARELID 511

QY 228 SLLQROESSVRLWKVLALVFGFATCATLFLIRKQYLQOE-----RLRLKQMQEFOE 281
DB 512 TIWKGNAANIIFNCLKEIDSTLYKNLFVDKNMKYIPTEDVSGLSLEEQRLQES--- 568

QY 282 HEAQLLSRAKPEDRESLSKACVCLSSFKSCVFLECGHVCSTCEYRALPEPKKPCICRQ 341
DB 569 -----RTCKVMDKESVSVFIPGHLVVCQEC---APSLKPCICRG 607

QY 342 AITRVIPLVNS 352
DB 608 IIRGTVRTFLS 618

RESULT 14
US-09-617-053A-8
; Sequence 8, Application US/09617053A
; Patent No. 6300492
; GENERAL INFORMATION:
; APPLICANT: Korneluk, Robert G
; APPLICANT: MacKenzie, Alexander E
; APPLICANT: Liston, Peter
; APPLICANT: Baird, Stephen
; APPLICANT: Tsang, Benjamin K
; APPLICANT: Pratt, Christine
; TITLE OF INVENTION: DETECTION AND MODULATION OF IAPS AND
; TITLE OF INVENTION: NAIP FOR THE DIAGNOSIS AND TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: DISEASE
; FILE REFERENCE: 07891/009003
; CURRENT APPLICATION NUMBER: US/09/617,053A
; CURRENT FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: US 08/800,929
; PRIOR FILING DATE: 1997-02-13
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; SEQ ID NO 8
; LENGTH: 618
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-617-053A-8

Query Match
Best Local Similarity 7.6%; Score 138.5; DB 3; Length 618;
Matches 67; Conservative 50; Mismatches 119; Indels 75; Gaps 13;

QY 82 QFVENCCKGVIQRLTLOEHKMWNRTHLWDCSKIIHQTNTVPFDLVPHEDGVDVAVRV 141
Db 343 EFVDEIQGRYPHLL--EQLLSTSDTTGEENADPPIH-----FGPGSSSEDVAVM 391

QY 142 LKPL--DSVDLGL-----ETVYEKHPHSIQSF---TDVIGHYISGERPKGIQE----TE 186
Db 392 NTPVVKSALEMGNRDLVKQTVLSKILTTGENTYKTVNDIVSALLNAEDEKREEKEKQAE 451

QY 187 EMLKVGATLTGVGEL-----VLDN-----NSVRLQPP---KQGMYYLSSOD-FD 227
Db 452 EMASDDLSLRKKNRMALFQOLTCTVLPILDNLLKANVINKQEHDI IKKQTOIPLQARELID 511

QY 228 SLQRQESSVRLMKVIALVGFATCATLFFILRKQYLQROE-----RLKQMQEEOE 281
Db 512 TIWVGNAANAIFKNCLKEIDSTLYKNLFVDKMKKYIPTEDVSGLSLEEQRLQEE--- 568

QY 282 HEAQLLSRAKPEDRESLSKACVCLSSFKSCVFLGCHGVCSCTECYRALPEPKKCPICRQ 341
Db 569 -----RTCKVCMDEKSVVFPICGHLVVCQEC---APSLRKCPICRG 607

QY 342 AITRVIPLVNS 352
Db 608 IIKGTVRTFLS 618

Search completed: November 6, 2004, 17:43:09
Job time : 41 secs
```

```
RESULT 15
US-09-201-936-8
; Sequence 8, Application US/09201936
; Patent No. 6541457
; GENERAL INFORMATION:
; APPLICANT: Korneluk, Robert G.
; APPLICANT: MacKenzie, Alexander E.
; APPLICANT: Baird, Stephen
; APPLICANT: Liston, Peter
; TITLE OF INVENTION: MAMMALIAN IAP GENE FAMILY, PRIMERS,
; FILE REFERENCE: 07891/003003
; CURRENT APPLICATION NUMBER: US/09/201,936
; EARLIER FILING DATE: 1998-12-01
; EARLIER APPLICATION NUMBER: 09/011,356
; EARLIER FILING DATE: 1998-02-04
; EARLIER APPLICATION NUMBER: PCT/IB96/01022
; EARLIER FILING DATE: 1996-08-05
; EARLIER APPLICATION NUMBER: 08/576,956
; EARLIER FILING DATE: 1995-12-22
; EARLIER APPLICATION NUMBER: 08/511,485
; EARLIER FILING DATE: 1995-08-04
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 618
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-201-936-8

Query Match
Best Local Similarity 7.6%; Score 138.5; DB 4; Length 618;
Matches 67; Conservative 50; Mismatches 119; Indels 75; Gaps 13;

QY 82 QFVENCCKGVIQRLTLOEHKMWNRTHLWDCSKIIHQTNTVPFDLVPHEDGVDVAVRV 141
Db 343 EFVDEIQGRYPHLL--EQLLSTSDTTGEENADPPIH-----FGPGSSSEDVAVM 391
```

